

**KINGDOM OF BAHRAIN
MINISTRY OF HEALTH**

**CANCER
INCIDENCE & MORTALITY
IN THE KINGDOM OF BAHRAIN**

STATISTICS AND TRENDS 2014

**MEDICAL REVIEW OFFICE
FEBRUARY 2016**



His Royal Highness
Prince Khalifa bin Salman Al Khalifa
The Prime Minister of the Kingdom of Bahrain



His Majesty
King Hamad bin Isa Al Khalifa
The King of the Kingdom of Bahrain



His Royal Highness
Prince Salman bin Hamad Al Khalifa
The Crown Prince, Deputy Supreme Commander of
Bahrain Defence Force and
First Deputy Prime Minister

CANCER

INCIDENCE & MORTALITY

IN THE KINGDOM OF BAHRAIN

STATISTICS AND TRENDS 2014

Prepared by

**DR. NAJAT MOHAMMED ABULFATEH
DR. FATEMA ABUHASSAN
DR. MAJEDA FEKRI
DR. EMAN JANAHI
MS. RESHMA CARLO
MRS. DALAL AL SALMAN**

Supervised by

DR. MOHAMMED AMIN AL AWADHI
Assistant Undersecretary of Training & Planning

MEDICAL REVIEW OFFICE

This report is printed annually.

Comments and suggestions concerning its contents are encouraged and could be sent to:

**MEDICAL REVIEW OFFICE
DIRECTORATE OF TRAINING & PLANNING
P. O. BOX 12, MANAMA
MINISTRY OF HEALTH**

Tel. +973 1728 6050

Fax +973 1728 6651

www.moh.gov.bh

To obtain extra copies of this report, please send a request to the above address.

PREFACE

According to figures from the World Health Organization, cancer is a leading cause of death worldwide. The disease has accounted for 8.2 million deaths in 2012 (around 13% of all deaths) and this rate is projected to exceed 13 million a year by 2030.¹ It can be reduced and controlled by implementing evidence-based strategies for cancer prevention, early detection of cancer and management of patients with cancer.

In the Kingdom of Bahrain, cancer is the fourth leading cause of death in both sexes combined following cardiovascular disease, endocrine disease, and other ill-defined causes. Compared to other Gulf countries, Bahrain has a higher incidence of cancers of the breast, lung, bladder, thyroid, uterus, and ovary. A rising trend in cancer incidence is likely to continue for years or even decades to come. In Bahraini males, lung cancer was observed to be the leading malignancy, followed by cancers of the colorectal, bladder, prostate, and leukemia. In Bahraini females, breast cancer remains the leading type followed by cancers of the colorectal, lung, thyroid, and uterus.

Between the years 1998 and 2014, there were a total of 8,013 incident cases of cancer (3,717 male and 4,296 female) among the Bahraini population in the Kingdom of Bahrain, averaging at approximately 471 new cases per year. In the year 2014 alone, 746 new cases of cancer (309 male and 437 female) were registered with the Bahrain Cancer Registry. Cancers of the breast (178), colorectum (72), lung (59), Non-Hodgkin's lymphoma [NHL] (41), and thyroid (36) constituted over half of the total cancer burden in that year (51.7%, 386 new cases).

I am delighted to introduce this comprehensive report on cancer incidence in the Kingdom of Bahrain for the year 2014. I hope this report will be able to stimulate the reading of clinicians, researchers, administrators, policy makers, and those interested in this field.

We welcome your constructive feedback to undertake the appropriate improvements to cancer registration in Bahrain, and to achieve our goal of better understanding cancer occurrence in the country, in order to provide health policy makers with reliable information for assessing and controlling the impact of cancer on the people of Bahrain.

Dr. Mohammed Amin Al Awadhi

Assistant Undersecretary, Directorate of Training & Planning

ACKNOWLEDGMENTS

This report is the result of years of data collection and months of planning and work to present this data in what we hope is an informative summary.

We give special thanks to **Her Excellency Faeqa bint Saeed Al Saleh**, Minister of Health, Bahrain, for her support without which this work would not have been possible.

Gratitude is felt toward **Dr. Mohammed Amin Al Awadhi**, Assistant Undersecretary for Training & Planning, for his continuous encouragement, support, and valuable criticism.

We would like to acknowledge and appreciate all staff of the Medical Review Office for their dedication, enthusiasm, and technical expertise in producing this report.

I express my deepest gratitude to all colleagues working in various institutions for their cooperation in notifying cancer cases to the Bahrain Cancer Registry.

The production of this report has been made possible by the active cooperation of consultants, general practitioners, pathology laboratories, medical records staff, information specialists, medical secretaries, clinical coders, and managers in the different Bahraini health facilities.

The Bahrain Cancer Registry is indebted to all those who have submitted data and whose support has been given over many years.

Finally yet importantly, this work is aimed only at the wellbeing of our patients and their better health.

Dr. Najat Abulfateh Ali
Chief, Medical Review Office

TABLE OF CONTENTS

| | |
|---|-----------|
| INTRODUCTION | 1 |
| BACKGROUND ON THE KINGDOM OF BAHRAIN | 4 |
| POPULATION STRUCTURE | 4 |
| GEOGRAPHIC DISTRIBUTION | 10 |
| BAHRAIN CANCER REGISTRY | 11 |
| BACKGROUND AND STRUCTURE | 11 |
| OBJECTIVES OF BAHRAIN CANCER REGISTRY | 11 |
| METHODS | 11 |
| TRENDS OF CANCER INCIDENCE 1998 – 2014 | 17 |
| CANCER INCIDENCE, 1998-2014 | 18 |
| MOST COMMON CANCERS IN BAHRAINIS, 1998-2014 | 24 |
| COMPARISONS OF CANCER INCIDENCE WITH THE GCC STATES | 37 |
| INTERNATIONAL COMPARISONS OF CANCER | 38 |
| CANCER INCIDENCE, 2014 | 40 |
| INCIDENCE OF MOST COMMON CANCERS 2014 | 45 |
| MOST COMMON CANCERS IN BAHRAINIS, 2014 | 46 |
| BREAST | 48 |
| COLORECTUM | 50 |
| LUNG | 52 |
| NON-HODGKIN'S LYMPHOMA | 54 |
| THYROID | 56 |
| BLADDER | 58 |
| PROSTATE | 60 |
| OVARY | 62 |
| BRAIN AND CENTRAL NERVOUS SYSTEM | 64 |

TABLE OF CONTENTS

| | |
|--|-----------|
| PANCREAS | 66 |
| CHILDHOOD CANCER 1998 – 2014..... | 68 |
| TRENDS OF CHILDHOOD CANCER INCIDENCE, 1998-2014 | 69 |
| MOST COMMON CANCERS IN BAHRAINI CHILDREN, 1998-2014..... | 73 |
| INCIDENCE OF CHILDHOOD CANCERS, 2014 | 76 |
| CANCER MORTALITY 2014 | 78 |
| TRENDS OF CANCER MORTALITY, 2014 | 79 |
| REFERENCES | 82 |

INTRODUCTION

Cancer is a major health problem in both developed and developing countries. The estimated number of new cases of cancer each year is expected to rise from 10 million in 2000 to 16 million by 2020.¹ This number continues to grow every year by 3 to 4%. Nearly 60% of the increase will occur in developing countries where healthcare facilities and patients care are limited. In the Eastern Mediterranean Region (EMR) cancer incidence is predicted to rise by 1.8-fold during the next decade.¹

Rapid improvements in the healthcare, together with the control of communicable diseases, increased life expectancy at birth, and rapid socioeconomic changes resulting in modified lifestyles such as the increased prevalence of tobacco use, decrease in physical activity, and rapid uptake of unhealthy food habits, has resulted in an increased incidence of cancer in the developing countries.¹

Every year cancer kills more than 6 million people worldwide. Cancer is the second most frequent cause of death in the majority of developed countries and is the fourth leading cause of death in the EMR after cardiovascular diseases, infectious diseases, and injuries.¹ The causes and types of cancer vary in different regions of the world but in most countries, there is hardly a family without a cancer victim.¹

Cancer involves more than 100 diseases with different etiologic factors, preventive approaches, and treatment modalities. However, 40% of all cancers are preventable, another 40% are curable if diagnosed early and treated promptly. The remaining 20% can be treated with palliative therapy to reduce suffering of cancer patients. Therefore, fighting against cancer necessitates integration between primary, secondary and tertiary medical care in any country.²

From January 1998 to December 2009, there were 119,288 newly diagnosed cancer cases among Gulf Cooperation Council (GCC) States' nationals, reported by the 6 National Cancer Registries (United Arab Emirates [UAE], Bahrain, Saudi Arabia, Oman, Qatar, and Kuwait); 58,629 cases (49.1%) were male and 60,659 (50.8%) were female.²

The average annual world age-standardized cancer incidence rates (ASR) during the 12-year period from 1998 to 2009 were found to be similar between GCC males and females (82.9 per 100,000 in males and 83.7 per 100,000 in females). In males, the ASRs per 100,000 people ranged between 75.7 in the Kingdom of Saudi Arabia (KSA) and 155.2 in Qatar, whereas in females, the ASRs per 100,000 people ranged between 75.2 in KSA and 180.3 in Qatar. The average annual age-specific incidence rates increase dramatically with advancing age in both genders.²

In the 6 GCC countries, breast cancer is the most common female cancer.^{2,3} Compared to all female cancers, the proportion of breast cancer ranged from 18.2% in Oman to 45.6% in Qatar and 37.1% in Bahrain. Bahrain and Qatar can be classified as medium breast cancer incidence areas whereas the UAE, KSA, and Oman are considered low incidence areas. A comparison of the ASRs of breast cancer from medium-incidence GCC countries with other countries showed that the GCC rates are about half those of the high-risk area countries like the United Kingdom, and similar to the rates in medium-risk countries such as the Philippines and Singapore.³

Bahrain has a higher incidence of cancers of the breast, lung, bladder, thyroid, uterus, and ovary. A rising trend in cancer incidence is likely to continue for years or even decades to come. In Bahraini males, lung cancer was observed to be the leading malignancy, followed by cancers of the large bowel, bladder, prostate, and leukemia. In Bahraini females, breast cancer remains the leading type followed by cancers of the large bowel, lung, thyroid, and uterus.^{4,5}

Between the years 1998 and 2014, there were a total of 8,013 incident cases of cancer (3,717 male and 4,296 female) among the Bahraini population in the Kingdom of Bahrain, averaging at approximately 471 new cases per year. In the year 2014 alone, 746 new cases of cancer (309 male and 437 female) were registered with the Bahrain Cancer Registry. Cancers of the breast (178), colorectum (72), lung (59), Non-Hodgkin's lymphoma [NHL] (41), and thyroid (36) constituted over half of the total cancer burden in that year (51.7%, 386 new cases).

In the Gulf Region, the Gulf Center for Cancer Registration (GCCR) was established in 1997 to provide reliable cancer incidence data for the Nationals of the GCC States. GCCR works under the jurisdiction of the Executive Office of the Health Ministers' Council for GCC States. The main office is located in the premises of the Research Center at the King Faisal Specialist Hospital and Research Center, KSA. The aggregated data from the 6 national cancer registries representing the 6 Gulf countries: UAE, Kingdom of Bahrain, KSA, Oman, Qatar, and Kuwait is considered to be the largest in Asia. The primary objective of the GCCR is to collect and classify information on all cancer cases in order to produce statistics on the occurrence of cancer in a defined population, to provide technical support for early detection and screening programs, and to facilitate epidemiological studies on cancer to provide a framework for assessing and controlling the impact of cancer on the GCC states' communities.

This initiative was the groundwork for the strategic plans (2004-2009 and 2010-2020) for Cancer Prevention and Control in the GCC states. Furthermore, a framework comprising 7 approaches and strategic actions has been developed to support Member States in developing national action plans and in the implementation of cancer control activities.

These strategies are in line with the World Health Organization (WHO) Global Strategy for the Prevention and Control of Non-communicable Diseases (2008-2013) and the WHO strategy against cancer through effective integration between primary, secondary, and tertiary prevention programs aiming to reduce preventable cancers, to treat curable cancers through early detection and management, and to relieve pain and improve quality of life through palliative care services.

BACKGROUND ON THE KINGDOM OF BAHRAIN

The **Kingdom of Bahrain** is a small island country and comprises of an archipelago of 33 islands situated near the western shores of the Arabian Gulf. The largest, accounting for 83% of the area, is the Bahrain Island and is 55 km (34 miles) long by 18 km (11 miles) wide.

Saudi Arabia lies to the west and is connected to Bahrain by the King Fahd Causeway. The peninsula of Qatar is to the southeast across the Gulf of Bahrain. The planned Qatar Bahrain Causeway will link Bahrain and Qatar and become the world's longest marine causeway.

The Kingdom of Bahrain is administratively divided into 4 Governorates/Regions. These are the Capital, Muharraq, Northern, and Southern Governorates

Bahrain today has a very high Human Development Index (44th highest in the world) and World Bank has identified it as a high-income economy. Bahrain is also a member of the United Nations, World Trade Organization, the Arab League, the Non-Aligned Movement, and the Organization of the Islamic Conference, as well as being a founding member of the Cooperation Council for the Arab States of the Gulf.

POPULATION STRUCTURE

According to Central Informatics Organization statistics (Table 1), the population of the Kingdom of Bahrain was 1,314,562 in 2014, of which 630,744 were Bahrainis. Of these, 320,839 were males and 309,905 were females. The non-Bahraini population in 2014 was 683,818; of these, 485,648 were males and 198,170 were females.

POPULATION CHANGE


The population at the last census in 2010 was 1,228,543, indicating a growth of 7% from 2010 to 2014 (Figure 1).⁶

Of the total population, the proportion of Bahrainis increased from 46% in 2010 to 48% in 2014. The percentage of non-Bahrainis decreased from 54% in 2010 to 52% in 2014 (Figure 2).

Table 1 Distribution of Population by Nationality, Age and Gender, 2014


| Age Groups | النوعية / الجنسية | | | | | | | | |
|--------------|-------------------|----------------|----------------|-----------------|----------------|----------------|----------------|----------------|----------------|
| | الجملة | | | Nationality/Sex | | | | | |
| | النوعين كلا | إناث | ذكور | بحريني غير | | | بحريني | | |
| | | | | النوعين كلا | إناث | ذكور | النوعين كلا | إناث | ذكور |
| Both sexes | Females | Males | Both sexes | Females | Males | Both sexes | Females | Males | |
| 0 - 4 | 100,596 | 49,196 | 51,400 | 27,644 | 13,547 | 14,097 | 72,952 | 35,649 | 37,303 |
| 5 - 9 | 89,812 | 43,976 | 45,836 | 22,748 | 11,139 | 11,609 | 67,064 | 32,837 | 34,227 |
| 10 - 14 | 79,179 | 38,476 | 40,703 | 17,740 | 8,586 | 9,154 | 61,439 | 29,890 | 31,549 |
| 15 - 19 | 73,589 | 35,441 | 38,148 | 13,255 | 6,183 | 7,072 | 60,334 | 29,258 | 31,076 |
| 20 - 24 | 105,972 | 43,485 | 62,487 | 47,406 | 14,822 | 32,584 | 58,566 | 28,663 | 29,903 |
| 25 - 29 | 177,999 | 56,994 | 121,005 | 124,681 | 30,941 | 93,740 | 53,318 | 26,053 | 27,265 |
| 30 - 34 | 170,791 | 53,844 | 116,947 | 124,195 | 30,997 | 93,198 | 46,596 | 22,847 | 23,749 |
| 35 - 39 | 135,098 | 45,877 | 89,221 | 93,897 | 25,729 | 68,168 | 41,201 | 20,148 | 21,053 |
| 40 - 44 | 106,200 | 34,875 | 71,325 | 73,325 | 18,513 | 54,812 | 32,875 | 16,362 | 16,513 |
| 45 - 49 | 87,287 | 31,707 | 55,580 | 52,399 | 13,851 | 38,548 | 34,888 | 17,856 | 17,032 |
| 50 - 54 | 69,440 | 26,644 | 42,796 | 37,554 | 10,475 | 27,079 | 31,886 | 16,169 | 15,717 |
| 55 - 59 | 51,854 | 19,288 | 32,566 | 26,285 | 6,523 | 19,762 | 25,569 | 12,765 | 12,804 |
| 60 - 64 | 29,136 | 11,219 | 17,917 | 11,591 | 3,286 | 8,305 | 17,545 | 7,933 | 9,612 |
| 65 - 69 | 14,889 | 6,306 | 8,583 | 4,981 | 1,545 | 3,436 | 9,908 | 4,761 | 5,147 |
| 70 - 74 | 9,878 | 4,593 | 5,285 | 2,597 | 829 | 1,768 | 7,281 | 3,764 | 3,517 |
| 75 - 79 | 6,366 | 3,063 | 3,303 | 1,603 | 521 | 1,082 | 4,763 | 2,542 | 2,221 |
| 80 - 84 | 3,757 | 1,788 | 1,969 | 1,008 | 321 | 687 | 2,749 | 1,467 | 1,282 |
| 85+ | 2,719 | 1,303 | 1,416 | 909 | 362 | 547 | 1,810 | 941 | 869 |
| Total | 1,314,562 | 508,075 | 806,487 | 683,818 | 198,170 | 485,648 | 630,744 | 309,905 | 320,839 |

Figure 1 Population Growth by Nationality, 2014



Source: Central Informatics Organization

Figure 2 Proportion of Population by Nationality, 2014




POPULATION GROWTH RATE

The average annual growth rate from the last census in 2010 to 2014 was 1.3% for the total population, 2.2% for Bahrainis and 0.5% for non-Bahrainis.

GENDER RATIO

In 2014, there were 103 Bahraini males per 100 Bahraini females (Figure 3). This indicates that the Bahraini society was homogeneous in term of gender, whereas the non-Bahraini community had a higher proportion of males among its members (gender ratio of 245 males per 100 females). This is due to the fact that foreign jobs usually attract more males than females.⁶

Figure 3 Gender Ratio by Nationality in 2014




Source: Central Informatics Organization

AGE COMPOSITION


Among the Bahraini population (Figure 4), the age composition was relatively the same as that observed during the last census in 2010. In 2014, the percentage of children aged less than 15 years was approximately 31.9% (vs. 31.8% in 2010), while the proportion of senior citizens aged 65 years old and above was 4.2% (vs. 4.1% in 2010). The majority of the Bahraini population was of working age (15-64 years old), the proportion was 63.9% in 2014 (vs. 64% in 2010). These figures demonstrate that the Bahraini community is beginning to enter a new phase of demographic transition, where the working-age population is the largest in number.⁶

Figure 4 Proportion of Bahraini Population by Broad Age Groups, 2014



Among the non-Bahrainis (Figure 5), the proportion of children aged less than 15 years was 10% in 2014 (the same as in 2010), while the proportion of the elderly (65 years old and above) rose to 1.6% in 2014 from 0.4% in 2010. Similar to the trend observed in the Bahraini population, the population of working age (15-64 years) constituted the majority and accounted for 88.4% of the total population in 2014, and appeared to have decreased slightly from 89.6% in 2010.⁶

Figure 5 Proportion of Non-Bahraini Population by Broad Age Groups, 2014



POPULATION PYRAMIDS IN 2014

The 2014 population pyramids for the Bahraini and non-Bahraini populations presented in Figure 6 and Figure 7, respectively, show the population-age structure by gender. Table 1 presents the age and gender distribution of the population by nationality.

The widening base of the Bahraini population pyramid indicates the larger proportion of younger age groups, while the narrowing at the top of the pyramid indicates the small proportion of the elderly. The distribution is seen to be similar for both male and female populations.

The pyramid for the non-Bahraini population, however, is different from its Bahraini counterpart. The base and apex of the pyramid are narrow indicating the small number of younger and elderly age groups, while the broad middle corresponds to the larger working-age population constituting of mostly males.⁶

Figure 6 Bahraini Population Pyramid, 2014





Figure 7 Non-Bahraini Population Pyramid, 2014



Source: Central Informatics Organization

GEOGRAPHIC DISTRIBUTION

In 2014, the majority of the total population (Bahrainis and non-Bahrainis) (63.4%) was concentrated within the Capital and Northern Governorate, where the percentages of population were 39.3% and 24.1%, respectively (Figure 8).⁵

Similar to the total population, over 61% of the Bahraini population was concentrated in the Northern and Capital governorates (35.3% and 26.4% respectively) (Figure 9).

Figure 8 Proportion of the Total Population in Bahrain by Governorate, 2014





Figure 9 Proportion of Bahrainis by Governorate, 2014



BAHRAIN CANCER REGISTRY

BACKGROUND AND STRUCTURE

According to the Ministerial Decree 5/1994, cancer notification became mandatory and all physicians in the Kingdom are obliged to report all cancer cases to the Bahrain Cancer Registry at the Medical Review Office, Ministry of Health (MOH). Due to technical difficulties, it was not until 1998 that comprehensive and reliable data complying with international standards became available at the registry. In 2006, the Civil Service Bureau (CSB) approved a position for Tumor Registrar within the organizational chart of the Medical Review Office (MRO), now occupied by a trained senior nurse who is responsible for data collection, coding and data entry.

OBJECTIVES OF BAHRAIN CANCER REGISTRY

1. To compile an accurate database on the incident cases of cancer in of Kingdom of Bahrain.
2. To monitor the trends of cancer, to guide policy makers in setting priorities for control and management of cancer.
3. To provide researchers and clinicians with population-based information on the number and types of cancer cases.

METHODS

A. DATA COLLECTION

Initially, cancer cases were notified using a paper-based notification form which collected only limited information on each case. In 2010, an electronic notification form was designed and made accessible to clinical staff via the intranet of the Ministry of Health. Another electronic form with more detailed information was designed and has been made accessible to private health care facilities through a password-secured access on the Ministry of Health webpage.

Cases are registered as having a malignant disease in the Bahrain Cancer Registry whether it was pathologically or clinically diagnosed.

Personal, clinical and tumor details are collected by the registry using a specially-designed registration form. Unlike the hospital-based cancer registry which collects detailed clinical information on treatment of cancer patients, the Bahrain Cancer Registry is a national population-based registry covering all residents in the country and collects information on epidemiological, clinical and pathological aspects of the disease. This includes personal data, type, anatomical site and histological data of the tumor. It also includes information on the tumor stage, basis of diagnosis and hospital of treatment and referral. Information is then entered into the registry database and checked for duplication and consistency using the CanReg4 software.

a) Active Collection

Active collection involves the Tumor Registrar visiting different sources and abstracting data on Cancer Registry Forms. Being the largest tertiary center for diagnosis and treatment of cancer, registrars visit the Salmaniya Medical Complex (SMC) 4 times a week and extract data to the notification forms. Similarly, other tertiary hospitals like Bahrain Defense Force (BDF) Hospital and King Hamad Hospital (KHUH) are visited once a month. Patients diagnosed abroad are traced through the Oncology Outpatient Register at the SMC and subsequently data are extracted from their medical records.

b) Passive Reporting

When a case of cancer is diagnosed, the attending staff of the relevant specialty or the medical records department at all governmental , private hospital , clinics and laboratories completes the notification forms and sends them to the registry.

c) Other Reporting Methods

In addition to passive notification, case finding and registration is enhanced by several approaches. Clinical records of patients admitted with cancer to the SMC, the main source of most cancer cases, are sorted out at the Medical Record Department (MRD) upon discharge and checked for their registration status. Unregistered cases are registered and information for registered cases is updated.

The registry also receives an annual list of cancer deaths from the Health Information Directorate (HID). Death cases are cross-matched with the registered cases in order to sort out the unmatched cases (Death Certificate Notifications - DCN) which are then followed-up for any clinical information on their malignancy and date of diagnosis. Also lists for cancer patients who are treated outside Bahrain are annually checked through contacting Health Information Directorate.

B. DATA CODING, ENTRY AND VALIDITY

The CanReg4 software program and International Classification of Diseases for Oncology ICDO-3 began to be used from 1998. This program has a duplicate entry checking facility, which avoids the same case being registered more than once. For this report, we used CanReg4. Validity checks are performed for consistency between items: site/histology, gender/site and age/site/histology combinations by CanReg4.

C. DATA ANALYSIS

Data is first checked for consistency and validity using the International Agency for Research on Cancer (IARC), 1998 software (CanReg4). Frequency distribution and incidence tables are generated using the CanReg4 program. Bar diagrams and graphs were made using Microsoft Excel.

The registry produces statistical reports that show the distribution of different types of cancer according to age, gender and nationality. These reports are being utilized by government health planners and policy makers to address the importance of the cancer problem, allocate resources and to evaluate cancer prevention and control activities.

Several GCC reports have been produced with statistics on cancer in GCC countries, the most recent of which is the report on Cancer Incidence among Nationals of the GCC States, 1998-2009.² Bahrain cancer statistics have also appeared in some international publications and journals.^{4,5} Available statistical reports on cancer incidence have been made accessible on the MOH intranet and internet webpage.

D. DEFINITIONS

Incidence

The number of new cancer cases in a defined population within a specific period.

Date of Diagnosis

The date documented on the histopathology report. For clinical cases, the date of diagnosis is the date stated in patient's case notes to have cancer.

Population at Risk

The part of the Bahraini population that is susceptible to have a specific cancer.

Crude Incidence Rate

The number of new cancer cases in the Bahraini population occurring within a Gregorian calendar year (1st January to 31st December) divided by the population at risk in the same period expressed per 100,000.

Age-specific Incidence Rate

The incidence rate in a specific age group.

Crude Mortality Rate

The number of deaths, with cancer as the underlying cause of death, occurring in a specified population during a year. Cancer mortality is usually expressed as the number of deaths due to cancer per 100,000 population. That is, **Mortality Rate = (Cancer Deaths / Population) × 100,000**

Multiple Primaries

Two or more abnormal growths of tissue occurring simultaneously. The neoplasms are histologically different and may be found in the same or different sites.

Unspecified tumors

Include unknown primaries.

Metastasis

The distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal and or visceral organs.

World Age-standardized Rate (ASR)

Age standardization is necessary when comparing several populations that differ with respect to age. Hence, the World Standard Population Table proposed by Segi (1960)⁸ and modified by Doll *et al* (1966)⁹, (Table 2) was used to adjust the crude incidence rates and to remove the confounding effect

of age. Therefore, the ASR could be used for comparison purposes with other rates where the same world standard population was used, especially those issued by the WHO's agency, and the IARC, in its periodic publication Cancer Incidence in Five Continents.

Truncated rates refer to age-standardized rates for a specific age range, such as 0-14 years in children.

Table 2 Age Structure of the World Standard Population used for Age Adjustment

| Age Group | Population |
|--------------|----------------|
| 00-04 | 12,000 |
| 05-09 | 10,000 |
| 10-14 | 9,000 |
| 15-19 | 9,000 |
| 20-24 | 8,000 |
| 25-29 | 8,000 |
| 30-34 | 6,000 |
| 35-39 | 6,000 |
| 40-44 | 6,000 |
| 45-49 | 6,000 |
| 50-54 | 5,000 |
| 55-59 | 4,000 |
| 60-64 | 4,000 |
| 65-69 | 3,000 |
| 70-74 | 2,000 |
| 75-79 | 1,000 |
| 80-84 | 500 |
| 85+ | 500 |
| Total | 100,000 |

E. COLLABORATION WITH REGIONAL AND INTERNATIONAL AGENCIES

a) GCC Cancer Control Committee

Bahrain is represented in this committee. The committee produces statistical reports and gives recommendations and advice to countries on issues of cancer control. It also monitors some performance indicators of national cancer control programs in each country.

b) IARC:

This is a branch of the WHO specialized in cancer research and control. It provides its member countries with technical support on cancer registration and provides evidence on cancer causes, efficacy of screening and treatment modalities. It also gathers the countries' data, checks its quality and publishes it if it fulfills the quality criteria. Bahrain cancer data for 1998-2002 has been published by the IARC along with the data from Kuwait and Oman. Last publication for Bahrain cancer data for the years 2003-2007 had been issued in volume X.

c) International Agency of Cancer Registries (IACR):

This is an NGO affiliated with IARC and jointly they provide technical support and training in cancer registration techniques, manuals and tools to the members. In this respect, they also provide the software for cancer data entry, validation and analysis, which is free of charge to members. Bahrain Cancer Registry is a voting and associate member in this organization.

TRENDS OF CANCER INCIDENCE 1998 – 2014

CANCER INCIDENCE, 1998-2014

Between January 1998 and December 2014, there were 8,013 newly diagnosed cases of cancer among the Bahraini population in the Kingdom of Bahrain with an average of 471 cases per year, of which 3,717 (46.4%) were males and 4,296 (53.6%) were females.

The average annual crude incidence cancer rate was 88.0 per 100,000 Bahraini males and 102.6 per 100,000 Bahraini females. The average annual world ASRs were 135.1 and 138.5 per 100,000 Bahraini males and females, respectively (Table 3).

The frequencies and incidence rates of cancers in Bahraini males and females are presented in Table 4 to Table 7.

Overall, there was an observed decline in the trend of average annual ASRs for Bahraini males over the 17-year period. On the other hand, the trend of average annual ASRs for Bahraini females did not change significantly over the same period (Figure 10).

The average annual age-specific incidence rates were observed to increase dramatically with advancing age in both sexes (Figure 11).

During the 17-year period, breast cancer (1,680 cases), lung cancer (803 cases), colorectal cancer (750 cases), NHL (400 cases) and leukemia (386 cases) constituted half of the total cancer burden (50.2%; 4,019 new cases).

Table 3 Distribution of Incident Cancer Cases among Bahrainis, 1998-2014

| GENDER | FREQUENCY | PERCENTAGE (%) | AVERAGE ANNUAL CRUDE INCIDENCE RATE | AVERAGE ANNUAL ASR (WORLD) |
|--------------|--------------|----------------|-------------------------------------|----------------------------|
| Male | 3,717 | 46.4 | 88.0 | 135.1 |
| Female | 4,296 | 53.6 | 102.6 | 138.5 |
| TOTAL | 8,013 | 100 | | |

TRENDS OF CANCER INCIDENCE – 1998-2014

Table 4 Frequency of Incident Cancer Cases among Bahraini Males, 1998-2014

| CANCER SITE | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | ICD (10TH) |
|-----------------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|--------------|
| Lip | 2 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | C00 |
| Tongue | 2 | 0 | 3 | 2 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 4 | 1 | 2 | 6 | C01-C02 |
| Mouth | 2 | 1 | 4 | 1 | 1 | 2 | 1 | 0 | 2 | 2 | 1 | 2 | 2 | 4 | 4 | 5 | 1 | C03-C06 |
| Salivary glands | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 2 | 0 | 1 | 2 | C07-C08 |
| Tonsil | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | C09 |
| Other oropharynx | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | C10 |
| Nasopharynx | 1 | 3 | 2 | 4 | 3 | 5 | 2 | 3 | 0 | 0 | 2 | 5 | 1 | 1 | 6 | 8 | 0 | C11 |
| Hypopharynx | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | C12-C13 |
| Pharynx unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | C14 |
| Esophagus | 4 | 4 | 3 | 4 | 9 | 4 | 5 | 3 | 4 | 3 | 4 | 1 | 1 | 4 | 4 | 2 | 5 | C15 |
| Stomach | 6 | 10 | 12 | 11 | 9 | 7 | 8 | 6 | 6 | 6 | 14 | 8 | 4 | 8 | 7 | 12 | 13 | C16 |
| Small intestine | 1 | 0 | 2 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 1 | 2 | 1 | 2 | C17 |
| Colorectum | 15 | 21 | 15 | 15 | 17 | 20 | 21 | 20 | 22 | 21 | 24 | 35 | 23 | 34 | 47 | 43 | 34 | C18-C21 |
| Liver | 4 | 3 | 8 | 7 | 7 | 6 | 12 | 3 | 6 | 6 | 6 | 6 | 9 | 14 | 6 | 8 | 11 | C22 |
| Gallbladder etc. | 2 | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 1 | 2 | 4 | 0 | 2 | 5 | 4 | 1 | C23-C24 |
| Pancreas | 4 | 6 | 4 | 3 | 11 | 6 | 5 | 9 | 5 | 8 | 6 | 9 | 8 | 6 | 13 | 6 | 16 | C25 |
| Nose, sinuses etc. | 0 | 2 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | C30-C31 |
| Larynx | 5 | 5 | 3 | 6 | 7 | 5 | 4 | 1 | 6 | 6 | 6 | 4 | 3 | 4 | 4 | 5 | 5 | C32 |
| Trachea, bronchus, lung | 38 | 38 | 35 | 44 | 36 | 33 | 29 | 28 | 35 | 35 | 30 | 22 | 41 | 31 | 28 | 34 | 45 | C33-C34 |
| Other thoracic organs | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | C37-C38 |
| Bone | 1 | 1 | 5 | 4 | 1 | 3 | 2 | 5 | 4 | 4 | 3 | 2 | 3 | 3 | 2 | 2 | 7 | C40-C41 |
| Melanoma of skin | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | C43 |
| Other skin | 2 | 6 | 7 | 4 | 3 | 5 | 2 | 6 | 3 | 3 | 7 | 1 | 3 | 6 | 3 | 3 | 4 | C44 |
| Mesothelioma | 1 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | 4 | 4 | 1 | 2 | 2 | 1 | 2 | 1 | C45 |
| Kaposi sarcoma | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C46 |
| Connective, soft tissue | 3 | 0 | 1 | 2 | 3 | 4 | 1 | 3 | 2 | 3 | 1 | 1 | 6 | 1 | 3 | 3 | 3 | C47-C49 |
| Breast | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 3 | 3 | 0 | 3 | 4 | 1 | 2 | 1 | 3 | C50 |
| Penis | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C60 |
| Prostate | 10 | 20 | 21 | 15 | 12 | 12 | 13 | 16 | 13 | 26 | 19 | 8 | 15 | 14 | 32 | 33 | 29 | C61 |
| Testis | 2 | 2 | 0 | 5 | 2 | 1 | 3 | 3 | 3 | 7 | 2 | 1 | 4 | 2 | 1 | 6 | 2 | C62 |
| Other male genital organs | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | C63 |
| Kidney, ureters etc | 8 | 5 | 7 | 4 | 6 | 7 | 8 | 7 | 7 | 3 | 5 | 8 | 5 | 9 | 10 | 10 | 14 | C64-C66; C68 |
| Bladder | 13 | 25 | 17 | 13 | 11 | 13 | 17 | 11 | 16 | 16 | 16 | 11 | 22 | 19 | 25 | 22 | 22 | C67 |
| Eye | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | C69 |
| Brain, nervous system | 4 | 4 | 5 | 4 | 7 | 7 | 6 | 6 | 6 | 13 | 11 | 8 | 9 | 11 | 10 | 10 | 14 | C70-C72 |
| Thyroid | 2 | 2 | 2 | 2 | 0 | 5 | 5 | 6 | 1 | 2 | 3 | 1 | 5 | 4 | 4 | 10 | 4 | C73 |
| Adrenal gland | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | C74 |
| Other Endocrine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | C75 |
| Hodgkin's disease | 2 | 5 | 7 | 0 | 2 | 3 | 7 | 7 | 2 | 6 | 4 | 5 | 7 | 4 | 10 | 10 | 7 | C81 |
| Non-Hodgkin lymphoma | 8 | 10 | 8 | 12 | 10 | 10 | 13 | 10 | 12 | 11 | 12 | 14 | 19 | 21 | 22 | 14 | 23 | C82-C85;C96 |
| Immunoproliferative disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C88 |
| Multiple myeloma | 3 | 4 | 4 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 2 | 1 | 4 | 5 | C90 |
| Lymphoid leukemia | 9 | 3 | 6 | 4 | 5 | 3 | 5 | 6 | 1 | 3 | 2 | 4 | 5 | 7 | 5 | 11 | 9 | C91 |
| Myeloid leukemia | 12 | 7 | 4 | 5 | 7 | 4 | 4 | 2 | 4 | 6 | 5 | 4 | 3 | 6 | 12 | 10 | 6 | C92-C94 |
| Leukemia unspecified | 2 | 1 | 0 | 1 | 0 | 3 | 1 | 4 | 3 | 8 | 4 | 2 | 8 | 7 | 3 | 3 | 1 | C95 |
| Other & unspecified | 11 | 10 | 6 | 8 | 9 | 9 | 6 | 6 | 8 | 10 | 5 | 10 | 6 | 5 | 14 | 8 | 10 | Other |
| TOTAL | 183 | 203 | 196 | 188 | 190 | 189 | 189 | 186 | 188 | 234 | 205 | 194 | 228 | 242 | 292 | 301 | 309 | |

TRENDS OF CANCER INCIDENCE – 1998-2014

Table 5 Frequency of Incident Cancer Cases among Bahraini Females, 1998-2014

| CANCER SITE | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | ICD (10TH) |
|-----------------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----------------|
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C00 |
| Tongue | 3 | 2 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 4 | 1 | 0 | 2 | 2 | 1 | C01-C02 |
| Mouth | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | C03-C06 |
| Salivary glands | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 3 | C07-C08 |
| Tonsil | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C09 |
| Other oropharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | C10 |
| Nasopharynx | 1 | 1 | 0 | 0 | 0 | 4 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | C11 |
| Hypopharynx | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | C12-C13 |
| Pharynx unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C14 |
| Esophagus | 1 | 1 | 1 | 4 | 3 | 1 | 2 | 4 | 3 | 0 | 1 | 1 | 1 | 4 | 1 | 1 | 3 | C15 |
| Stomach | 7 | 6 | 7 | 7 | 4 | 8 | 6 | 5 | 5 | 5 | 4 | 7 | 8 | 6 | 10 | 6 | 4 | C16 |
| Small intestine | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 2 | C17 |
| Colorectum | 10 | 7 | 11 | 8 | 11 | 12 | 15 | 13 | 20 | 25 | 22 | 16 | 23 | 30 | 33 | 29 | 38 | C18-C21 |
| Liver | 1 | 5 | 8 | 1 | 4 | 5 | 2 | 5 | 4 | 5 | 8 | 4 | 2 | 6 | 12 | 5 | 9 | C22 |
| Gallbladder etc. | 1 | 0 | 2 | 1 | 2 | 0 | 0 | 2 | 2 | 2 | 3 | 2 | 2 | 5 | 1 | 5 | 3 | C23-C24 |
| Pancreas | 3 | 5 | 3 | 4 | 2 | 1 | 5 | 6 | 6 | 4 | 7 | 4 | 7 | 7 | 5 | 9 | 5 | C25 |
| Nose, sinuses etc. | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | C30-C31 |
| Larynx | 2 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | C32 |
| Trachea, bronchus, lung | 19 | 12 | 14 | 8 | 13 | 12 | 17 | 13 | 11 | 6 | 21 | 11 | 17 | 9 | 12 | 12 | 14 | C33-C34 |
| Other thoracic organs | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | C37-C38 |
| Bone | 2 | 2 | 1 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 3 | 2 | 0 | 3 | 0 | 1 | 5 | C40-C41 |
| Melanoma of skin | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C43 |
| Other skin | 3 | 4 | 2 | 3 | 0 | 2 | 2 | 3 | 4 | 2 | 1 | 0 | 1 | 1 | 0 | 5 | 3 | C44 |
| Mesothelioma | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | C45 |
| Kaposi sarcoma | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | C46 |
| Connective, soft tissue | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 2 | 2 | 0 | 1 | 2 | 2 | 2 | 3 | 7 | 1 | C47;C49 |
| Breast | 43 | 68 | 82 | 91 | 54 | 73 | 73 | 89 | 84 | 120 | 93 | 86 | 107 | 110 | 135 | 173 | 175 | C50 |
| Cervix Uteri | 12 | 9 | 6 | 6 | 6 | 9 | 5 | 10 | 6 | 11 | 13 | 5 | 6 | 7 | 7 | 10 | 9 | C53 |
| Corpus Uteri | 7 | 5 | 3 | 8 | 11 | 7 | 12 | 5 | 5 | 14 | 4 | 9 | 16 | 15 | 10 | 17 | 17 | C54 |
| Uterus unspecified | 1 | 0 | 3 | 2 | 3 | 0 | 2 | 3 | 3 | 11 | 4 | 4 | 2 | 4 | 5 | 2 | 5 | C55 |
| Ovary | 13 | 7 | 13 | 13 | 5 | 12 | 10 | 10 | 13 | 6 | 10 | 8 | 9 | 18 | 23 | 14 | 27 | C56 |
| Other female genital organs | 0 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 3 | 2 | 1 | 3 | 1 | 6 | C51-C52; C57 |
| Placenta | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | C58 |
| Kidney, ureters etc. | 2 | 6 | 8 | 5 | 4 | 5 | 4 | 4 | 3 | 6 | 7 | 0 | 0 | 3 | 5 | 2 | 4 | C64-C66; C68 |
| Bladder | 4 | 6 | 3 | 6 | 2 | 2 | 2 | 3 | 3 | 7 | 1 | 2 | 6 | 9 | 4 | 2 | 8 | C67 |
| Eye | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | C69 |
| Brain, nervous system | 0 | 3 | 1 | 1 | 3 | 4 | 4 | 3 | 7 | 1 | 5 | 4 | 9 | 9 | 4 | 8 | 8 | C70-C72 |
| Thyroid | 7 | 16 | 12 | 11 | 11 | 11 | 13 | 18 | 8 | 11 | 11 | 5 | 10 | 11 | 12 | 14 | 32 | C73 |
| Adrenal gland | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | C74 |
| Other endocrine glands | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | C75 |
| Hodgkin's disease | 1 | 4 | 3 | 7 | 0 | 2 | 1 | 5 | 2 | 3 | 2 | 5 | 2 | 2 | 5 | 10 | 7 | C81 |
| Non-Hodgkin lymphoma | 6 | 7 | 8 | 6 | 9 | 5 | 10 | 11 | 6 | 9 | 8 | 6 | 14 | 18 | 12 | 18 | 18 | C82-C85;C96 |
| Immunoproliferative disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C88 |
| Multiple Myeloma | 2 | 1 | 2 | 1 | 2 | 0 | 1 | 3 | 1 | 5 | 3 | 4 | 4 | 5 | 2 | 5 | 2 | C90 |
| Lymphoid leukemia | 5 | 2 | 4 | 2 | 2 | 0 | 5 | 2 | 2 | 1 | 4 | 2 | 1 | 3 | 3 | 1 | 2 | C91 |
| Myeloid leukemia | 7 | 4 | 1 | 3 | 4 | 4 | 4 | 4 | 3 | 2 | 7 | 5 | 4 | 5 | 4 | 1 | 8 | C92-C94 |
| Leukemia unspecified | 1 | 0 | 1 | 2 | 1 | 0 | 1 | 1 | 7 | 3 | 1 | 3 | 2 | 7 | 1 | 3 | 1 | C95 |
| Other & unspecified | 3 | 8 | 8 | 3 | 4 | 4 | 7 | 8 | 10 | 5 | 7 | 3 | 8 | 7 | 5 | 9 | 10 | Other |
| TOTAL | 173 | 204 | 212 | 210 | 163 | 190 | 213 | 238 | 228 | 269 | 257 | 212 | 269 | 313 | 327 | 381 | 437 | |

TRENDS OF CANCER INCIDENCE – 1998-2014

Table 6 World Age-Standardized Incidence Rates of Cancers in Bahraini Males, 1998-2014

| CANCER SITE | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | ICD (10TH) |
|---------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Lip | 1.7 | 0.0 | 1.1 | 0.0 | 1.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.9 | 0.4 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C00 |
| Tongue | 1.8 | 0.0 | 2.8 | 1.8 | 1.7 | 1.8 | 0.0 | 0.0 | 0.7 | 0.8 | 0.0 | 0.4 | 1.0 | 2.0 | 0.3 | 0.8 | 2.3 | C01-C02 |
| Mouth | 2.1 | 2.5 | 2.5 | 0.0 | 0.9 | 0.7 | 0.0 | 0.0 | 1.6 | 0.9 | 0.5 | 1.1 | 0.7 | 1.7 | 2.4 | 2.2 | 0.3 | C03-C06 |
| Salivary glands | 0.6 | 0.8 | 2.8 | 0.8 | 0.0 | 0.0 | 0.0 | 0.9 | 1.8 | 0.8 | 0.0 | 0.0 | 0.0 | 1.2 | 0.0 | 0.4 | 0.7 | C07-C08 |
| Tonsil | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.0 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | C09 |
| Other oropharynx | 1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | C10 |
| Nasopharynx | 0.5 | 2.2 | 1.8 | 1.9 | 2.7 | 3.5 | 1.8 | 2.0 | 0.0 | 0.0 | 0.7 | 2.4 | 0.4 | 0.3 | 2.4 | 2.9 | 0.0 | C11 |
| Hypopharynx | 0.0 | 2.0 | 0.0 | 0.0 | 0.8 | 1.0 | 0.0 | 1.5 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | C12-C13 |
| Pharynx unspecified | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C14 |
| Esophagus | 3.7 | 2.6 | 2.5 | 3.6 | 8.5 | 3.7 | 4.9 | 2.3 | 2.9 | 2.0 | 2.4 | 0.7 | 0.4 | 2.0 | 1.5 | 0.9 | 2.3 | C15 |
| Stomach | 5.9 | 10.0 | 11.2 | 8.6 | 7.6 | 5.8 | 6.7 | 4.9 | 4.1 | 2.9 | 7.9 | 4.6 | 2.1 | 4.2 | 3.6 | 5.4 | 5.8 | C16 |
| Small intestine | 0.9 | 0.0 | 1.8 | 0.0 | 0.0 | 0.8 | 0.7 | 0.7 | 1.0 | 0.0 | 1.5 | 1.1 | 0.6 | 0.6 | 1.0 | 0.4 | 0.6 | C17 |
| Colorectum | 14.6 | 17.3 | 12.5 | 11.7 | 12.5 | 13.5 | 16.8 | 15.5 | 15.9 | 10.7 | 13.0 | 18.8 | 11.6 | 16.0 | 21.9 | 18.9 | 13.3 | C18-21 |
| Liver | 4.2 | 2.4 | 7.4 | 6.4 | 5.4 | 4.2 | 9.7 | 2.1 | 4.1 | 2.7 | 3.4 | 3.4 | 4.1 | 6.2 | 2.5 | 3.2 | 4.1 | C22 |
| Gallbladder etc. | 2.2 | 1.1 | 0.0 | 0.0 | 0.7 | 0.0 | 0.9 | 1.3 | 1.4 | 0.9 | 1.2 | 2.1 | 0.0 | 1.3 | 2.1 | 1.6 | 0.6 | C23-C24 |
| Pancreas | 3.5 | 5.4 | 4.1 | 2.6 | 8.6 | 5.2 | 4.5 | 6.2 | 4.1 | 4.6 | 3.1 | 4.8 | 4.7 | 2.7 | 6.2 | 2.8 | 7.1 | C25 |
| Nose, sinuses etc. | 0.0 | 1.6 | 0.0 | 0.4 | 0.0 | 0.4 | 0.5 | 0.6 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 1.1 | 0.0 | C30-C31 |
| Larynx | 3.9 | 5.3 | 2.4 | 5.3 | 4.5 | 4.1 | 3.4 | 0.7 | 4.8 | 4.3 | 3.3 | 2.6 | 1.6 | 1.7 | 1.7 | 2.1 | 2.0 | C32 |
| Trachea, bronchus, lung | 36.7 | 34.1 | 33.5 | 36.0 | 31.4 | 27.9 | 25.2 | 21.9 | 27.6 | 22.6 | 17.8 | 12.9 | 21.7 | 15.8 | 14.1 | 15.8 | 20.0 | C33-C34 |
| Other thoracic organs | 0.5 | 1.0 | 0.0 | 1.3 | 1.0 | 0.8 | 0.5 | 0.7 | 0.4 | 1.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.9 | 0.6 | C37-C38 |
| Bone | 1.0 | 0.7 | 3.5 | 3.7 | 0.3 | 3.3 | 1.3 | 2.2 | 1.4 | 1.3 | 1.3 | 0.7 | 0.9 | 0.9 | 0.6 | 0.6 | 2.4 | C40-C41 |
| Melanoma of skin | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | 0.0 | 0.0 | 0.0 | 0.3 | 0.5 | C43 |
| Other skin | 1.6 | 6.4 | 5.8 | 4.4 | 2.2 | 4.6 | 1.3 | 4.2 | 2.0 | 1.9 | 3.2 | 0.3 | 1.4 | 3.0 | 1.6 | 1.0 | 1.5 | C44 |
| Mesothelioma | 1.0 | 0.0 | 0.0 | 0.0 | 1.0 | 1.6 | 1.9 | 0.8 | 1.5 | 3.1 | 2.4 | 0.5 | 1.0 | 1.4 | 0.3 | 0.9 | 0.5 | C45 |
| Kaposi sarcoma | 0.0 | 0.0 | 0.0 | 1.1 | 0.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C46 |
| Connective, soft tissue | 2.5 | 0.0 | 1.0 | 1.2 | 1.6 | 2.8 | 0.4 | 1.8 | 1.4 | 1.5 | 0.4 | 0.4 | 2.2 | 0.4 | 0.9 | 1.3 | 1.6 | C47-C49 |
| Breast | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 1.9 | 0.7 | 0.0 | 1.9 | 1.6 | 0.0 | 1.8 | 1.9 | 0.4 | 1.3 | 0.3 | 1.1 | C50 |
| Penis | 0.0 | 0.0 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C60 |
| Prostate | 9.6 | 19.1 | 19.3 | 11.8 | 9.4 | 9.2 | 10.0 | 13.2 | 10.4 | 15.1 | 11.4 | 4.6 | 8.0 | 7.4 | 17.0 | 16.8 | 14.2 | C61 |
| Testis | 1.0 | 0.9 | 0.0 | 2.5 | 0.8 | 0.4 | 1.9 | 1.4 | 1.8 | 3.0 | 0.7 | 0.4 | 1.3 | 0.7 | 0.3 | 1.8 | 0.6 | C62 |
| Other male genital organs | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | C63 |
| Kidney, ureter etc. | 5.9 | 4.8 | 6.5 | 3.3 | 5.0 | 6.0 | 5.0 | 5.0 | 4.6 | 1.5 | 2.9 | 3.7 | 2.6 | 3.8 | 3.5 | 4.9 | 4.7 | C64-C66; C68 |
| Bladder | 12.6 | 23.6 | 14.5 | 10.3 | 9.0 | 11.7 | 14.6 | 8.0 | 12.8 | 9.5 | 9.3 | 6.4 | 11.5 | 9.8 | 12.6 | 10.5 | 10.1 | C67 |
| Eye | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 | C69 |
| Brain, nervous system | 2.3 | 3.4 | 3.2 | 2.1 | 4.4 | 4.5 | 3.4 | 3.5 | 3.1 | 6.1 | 4.7 | 4.0 | 3.9 | 4.0 | 4.0 | 3.4 | 4.9 | C70-C72 |
| Thyroid | 1.3 | 1.2 | 1.6 | 1.7 | 0.0 | 2.4 | 3.4 | 3.7 | 0.7 | 1.2 | 2.1 | 0.4 | 2.2 | 1.5 | 1.9 | 4.0 | 1.3 | C73 |
| Adrenal gland | 0.0 | 0.5 | 0.7 | 0.5 | 0.0 | 0.0 | 5.0 | 0.5 | 0.5 | 0.0 | 0.0 | 0.0 | 0.6 | 0.0 | 0.3 | 1.0 | 0.3 | C74 |
| Other Endocrine glands | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.0 | C74 |
| Hodgkin's disease | 0.8 | 2.8 | 3.5 | 0.0 | 0.7 | 1.2 | 3.5 | 2.9 | 0.8 | 2.5 | 1.4 | 1.7 | 2.4 | 1.4 | 3.1 | 3.2 | 2.1 | C81 |
| Non-Hodgkin lymphoma | 6.3 | 12.0 | 5.6 | 6.9 | 7.7 | 6.6 | 8.5 | 5.0 | 6.5 | 4.6 | 5.2 | 6.2 | 8.5 | 9.7 | 8.8 | 4.9 | 8.5 | C82-C85;C96 |
| Immunoproliferative dis | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C88 |
| Multiple myeloma | 3.2 | 3.8 | 3.2 | 1.0 | 1.7 | 0.9 | 0.7 | 1.4 | 1.5 | 0.9 | 1.6 | 2.2 | 1.4 | 0.9 | 0.6 | 1.6 | 2.1 | C90 |
| Lymphoid leukemia | 6.6 | 1.8 | 2.9 | 2.3 | 3.1 | 1.7 | 2.9 | 2.9 | 0.8 | 1.6 | 0.9 | 1.8 | 1.7 | 2.5 | 2.1 | 4.0 | 2.7 | C91 |
| Myeloid leukemia | 9.1 | 5.1 | 4.2 | 3.1 | 3.4 | 2.4 | 2.7 | 1.6 | 2.4 | 2.8 | 1.9 | 1.4 | 1.0 | 2.3 | 5.0 | 3.9 | 1.9 | C92-C94 |
| Leukemia unspecified | 1.8 | 0.5 | 0.0 | 0.9 | 0.0 | 0.8 | 0.4 | 2.3 | 1.4 | 3.2 | 1.6 | 0.7 | 3.9 | 2.5 | 1.2 | 1.0 | 0.3 | C95 |
| Other & unspecified | 9.5 | 7.8 | 5.6 | 5.7 | 7.2 | 7.7 | 4.2 | 4.0 | 6.1 | 5.5 | 2.7 | 5.4 | 3.5 | 1.9 | 6.3 | 3.9 | 4.7 | Other |
| TOTAL | 160.9 | 182.7 | 168.3 | 142.9 | 145.3 | 143.1 | 147.4 | 128.3 | 133.0 | 126.7 | 109.3 | 100.9 | 109.8 | 111.2 | 132.7 | 128.9 | 125.9 | |

TRENDS OF CANCER INCIDENCE – 1998-2014

Table 7 World Age-Standardized Incidence Rates of Cancers in Bahraini Females, 1998-2014

| CANCER SITE | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | ICD (10TH) |
|-----------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|-------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Lip | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C00 |
| Tongue | 2.4 | 0.9 | 0.0 | 1.3 | 0.0 | 0.0 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 2.2 | 0.7 | 0.0 | 0.6 | 1.0 | 0.3 | C01-C02 |
| Mouth | 1.0 | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.3 | 0.3 | C03-C06 |
| Salivary glands | 0.0 | 0.0 | 0.5 | 0.4 | 0.0 | 0.0 | 0.4 | 0.0 | 1.2 | 0.3 | 0.4 | 0.4 | 0.3 | 0.0 | 0.3 | 1.2 | 1.2 | C07-C08 |
| Tonsil | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C09 |
| Other oropharynx | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.6 | 0.3 | C10 |
| Nasopharynx | 0.6 | 1.1 | 0.0 | 0.0 | 0.0 | 2.9 | 0.0 | 0.9 | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.3 | 0.3 | 0.0 | 0.4 | C11 |
| Hypopharynx | 1.0 | 1.0 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 0.9 | 0.0 | 0.0 | C12-C13 |
| Pharynx unspecified | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C14 |
| Esophagus | 1.1 | 1.0 | 1.0 | 3.1 | 1.8 | 0.9 | 1.2 | 3.3 | 2.5 | 0.0 | 0.7 | 0.5 | 0.4 | 1.9 | 0.3 | 0.3 | 1.7 | C15 |
| Stomach | 6.5 | 5.4 | 6.5 | 4.1 | 3.0 | 5.2 | 4.0 | 3.8 | 3.3 | 2.5 | 2.0 | 4.1 | 3.3 | 2.5 | 3.3 | 2.4 | 1.8 | C16 |
| Small intestine | 0.0 | 2.0 | 1.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.0 | 0.8 | 0.0 | 0.6 | 0.0 | 0.0 | 0.0 | 1.0 | 0.3 | 0.9 | C17 |
| Colorectum | 6.3 | 6.4 | 9.0 | 5.3 | 6.5 | 8.7 | 10.3 | 8.5 | 13.4 | 13.3 | 10.4 | 7.2 | 11.0 | 13.6 | 13.3 | 12.6 | 14.7 | C18-C21 |
| Liver | 1.1 | 4.9 | 7.3 | 0.5 | 3.5 | 3.4 | 1.4 | 3.8 | 3.3 | 2.9 | 4.0 | 2.4 | 0.8 | 3.0 | 5.5 | 2.2 | 3.8 | C22 |
| Gallbladder etc. | 1.1 | 0.0 | 1.4 | 0.9 | 1.9 | 0.0 | 0.0 | 1.1 | 1.6 | 1.0 | 1.7 | 1.4 | 1.2 | 2.0 | 0.4 | 2.6 | 1.2 | C23-C24 |
| Pancreas | 3.0 | 4.8 | 2.1 | 2.8 | 1.3 | 0.8 | 3.4 | 5.0 | 4.0 | 2.5 | 3.6 | 1.6 | 3.8 | 3.2 | 2.5 | 4.0 | 1.9 | C25 |
| Nose, sinuses etc. | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | 0.0 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | C30-C31 |
| Larynx | 1.8 | 1.0 | 0.0 | 1.0 | 0.0 | 1.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.5 | C32 |
| Trachea, bronchus, lung | 19.0 | 11.8 | 12.3 | 7.2 | 11.4 | 10.2 | 13.5 | 10.4 | 8.5 | 3.4 | 12.1 | 6.9 | 8.6 | 4.5 | 5.2 | 5.9 | 6.1 | C33-C34 |
| Other thoracic organs | 0.0 | 1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 0.0 | 0.0 | 0.5 | 0.5 | 0.0 | 0.4 | 0.3 | 0.0 | 0.0 | 0.0 | C37-C38 |
| Bone | 0.8 | 1.4 | 1.4 | 0.0 | 0.0 | 0.8 | 0.0 | 0.4 | 0.4 | 0.0 | 1.0 | 0.8 | 0.0 | 1.2 | 0.0 | 0.3 | 1.7 | C40-C41 |
| Melanoma of skin | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C43 |
| Other skin | 2.4 | 4.5 | 1.9 | 2.6 | 0.0 | 1.5 | 1.3 | 2.0 | 3.2 | 1.0 | 0.8 | 0.0 | 0.7 | 0.4 | 0.0 | 1.8 | 1.0 | C44 |
| Mesothelioma | 0.0 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.0 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.5 | C45 |
| Kaposi sarcoma | 0.0 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | C46 |
| Connective, soft tissue | 0.0 | 0.5 | 0.0 | 0.0 | 1.3 | 0.4 | 0.0 | 1.0 | 1.1 | 0.0 | 0.3 | 0.7 | 0.7 | 0.6 | 1.3 | 2.8 | 0.3 | C47;C49 |
| Breast | 30.8 | 48.4 | 57.2 | 56.9 | 34.6 | 44.8 | 45.8 | 59.1 | 56.4 | 58.1 | 43.6 | 37.7 | 43.7 | 45.8 | 53.9 | 67.7 | 65.6 | C50 |
| Other female genital organs | 0.0 | 1.9 | 0.9 | 1.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 0.0 | 1.1 | 1.6 | 1.0 | 0.3 | 1.3 | 0.4 | 2.4 | C51-C52; C57 |
| Cervix Uteri | 9.9 | 6.3 | 4.4 | 4.6 | 4.9 | 6.7 | 3.8 | 7.1 | 4.1 | 4.7 | 6.6 | 2.7 | 2.7 | 3.5 | 2.9 | 3.7 | 3.1 | C53 |
| Corpus Uteri | 5.1 | 4.3 | 2.5 | 5.2 | 8.2 | 5.7 | 9.4 | 4.0 | 3.8 | 8.1 | 2.0 | 4.4 | 6.7 | 6.8 | 4.1 | 8.0 | 6.7 | C54 |
| Uterus unspecified | 0.6 | 0.0 | 3.0 | 1.6 | 2.5 | 0.0 | 1.7 | 2.0 | 2.3 | 6.7 | 2.4 | 1.9 | 0.7 | 1.6 | 1.8 | 0.9 | 2.2 | C55 |
| Ovary | 10.6 | 6.4 | 8.2 | 8.3 | 3.7 | 9.0 | 7.8 | 5.7 | 8.0 | 3.0 | 5.2 | 3.0 | 3.5 | 8.6 | 9.9 | 4.7 | 9.7 | C56 |
| Placenta | 0.4 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.4 | 0.4 | 0.4 | 0.3 | 0.0 | 0.0 | 0.3 | 0.0 | 0.4 | 0.0 | 0.0 | C58 |
| Kidney, ureter, pelvis etc. | 2.0 | 4.2 | 5.6 | 4.2 | 1.3 | 4.2 | 2.0 | 2.5 | 1.9 | 3.3 | 2.8 | 0.0 | 0.0 | 1.1 | 1.9 | 0.7 | 1.6 | C64-C66; C68 |
| Bladder | 3.1 | 5.4 | 3.7 | 5.0 | 1.7 | 1.6 | 1.7 | 2.4 | 1.7 | 2.7 | 0.3 | 1.4 | 2.5 | 4.7 | 1.7 | 1.0 | 3.7 | C67 |
| Eye | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C69 |
| Brain, nervous system | 0.0 | 1.0 | 0.9 | 0.0 | 2.2 | 2.6 | 1.7 | 2.0 | 3.8 | 0.9 | 2.1 | 1.5 | 4.1 | 3.7 | 1.8 | 3.0 | 3.0 | C70-C72 |
| Thyroid | 3.7 | 10.7 | 8.1 | 7.7 | 6.4 | 7.1 | 6.4 | 10.8 | 3.5 | 4.9 | 4.2 | 2.2 | 3.5 | 5.0 | 4.1 | 4.8 | 11.2 | C73 |
| Adrenal gland | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.0 | 0.3 | C74 |
| Other endocrine glands | 0.0 | 0.4 | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.3 | 0.3 | C75 |
| Hodgkin's disease | 1.0 | 2.9 | 1.8 | 3.5 | 0.0 | 1.3 | 0.4 | 2.5 | 0.8 | 1.5 | 0.6 | 2.5 | 1.0 | 0.6 | 1.9 | 3.3 | 2.2 | C81 |
| Non-Hodgkin lymphoma | 4.4 | 8.3 | 5.1 | 4.3 | 7.8 | 3.7 | 5.8 | 7.7 | 4.9 | 3.5 | 3.9 | 2.6 | 6.0 | 7.8 | 5.5 | 7.6 | 6.2 | C82-C85;C96 |
| Immunoproliferative dis | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C88 |
| Multiple Myeloma | 2.0 | 1.0 | 1.9 | 1.0 | 1.9 | 0.0 | 0.8 | 2.5 | 0.8 | 2.7 | 1.2 | 1.6 | 2.2 | 2.1 | 0.9 | 2.3 | 0.8 | C88; C90 |
| Lymphoid leukemia | 2.7 | 0.8 | 1.7 | 0.8 | 0.9 | 0.0 | 2.5 | 1.3 | 1.4 | 0.4 | 1.6 | 0.8 | 0.3 | 1.3 | 1.4 | 0.3 | 0.6 | C91 |
| Myeloid leukemia | 3.7 | 3.3 | 0.0 | 0.9 | 2.6 | 1.6 | 2.5 | 2.7 | 1.8 | 1.1 | 3.0 | 2.6 | 1.4 | 1.9 | 1.5 | 0.3 | 2.8 | C92-C94 |
| Leukemia unspecified | 1.0 | 0.0 | 0.9 | 1.4 | 0.7 | 0.0 | 0.9 | 0.5 | 2.9 | 1.3 | 0.4 | 1.4 | 0.7 | 3.2 | 0.3 | 1.0 | 0.5 | C95 |
| Other & unspecified | 2.9 | 6.8 | 8.1 | 3.4 | 3.5 | 4.4 | 5.9 | 6.2 | 7.6 | 2.5 | 3.2 | 1.6 | 4.0 | 3.2 | 2.6 | 4.5 | 4.6 | Other |
| TOTAL | 134.0 | 162.9 | 160.3 | 140.2 | 114.1 | 128.9 | 140.0 | 161.6 | 151.4 | 133.9 | 122.3 | 99.9 | 116.2 | 136.0 | 133.4 | 154.0 | 166.2 | |

Figure 10 Age-Standardized Incidence Rates of Cancers among Bahrainis by Year, 1998-2014





Figure 11 Average Annual Age-Specific Incidence Rates of Cancers among Bahrainis, 1998-2014



MOST COMMON CANCERS IN BAHRAINIS, 1998-2014


Between 1998 and 2014, lung cancer was observed to be the leading malignancy in Bahraini males (582 new cases), followed by cancers of the colorectal, prostate, bladder, and leukemia. Breast cancer was the leading malignancy in Bahraini females with 1,656 new cases, followed by cancers of the colorectal, lung, thyroid, and ovary (Table 8 and Figure 12).

Trends of average annual ASRs and age-specific incidence rates of the 5 common cancers among Bahraini males and females are presented in Figure 13 to Figure 16.

Table 8 Most Common Cancers among Bahraini Nationals, 1998-2014

| MALES (N = 3,717) | | | | FEMALES (N = 4,296) | | | |
|-------------------|-----|------|------|---------------------|------|------|------|
| Site | No. | % | ASR | Site | No. | % | ASR |
| Lung | 582 | 15.7 | 24.4 | Breast | 1656 | 38.5 | 50.0 |
| Colorectal | 427 | 11.5 | 15.0 | Colorectal | 323 | 7.5 | 10.0 |
| Prostate | 308 | 8.3 | 12.1 | Lung | 221 | 5.1 | 9.2 |
| Bladder | 289 | 7.8 | 11.6 | Thyroid | 213 | 5.0 | 6.1 |
| Leukemia | 240 | 6.5 | 7.0 | Ovary | 211 | 4.9 | 6.8 |
| NHL | 229 | 6.2 | 7.1 | NHL | 171 | 4.0 | 5.6 |
| Stomach | 147 | 4.0 | 6.0 | Corpus Uteri | 165 | 3.8 | 5.6 |
| Unspecified | 141 | 3.8 | 5.4 | Leukemia | 146 | 3.4 | 4.1 |
| Brain & CNS | 135 | 3.6 | 3.8 | Cervix Uteri | 137 | 3.2 | 4.8 |
| Pancreas | 125 | 3.4 | 4.7 | Unspecified | 109 | 2.5 | 4.4 |

Figure 12 Most Common Cancers among Bahraini Nationals by ASR, 1998-2014



MOST COMMON CANCERS IN MALES

LUNG CANCER

During the 17-year period, lung cancer accounted for 15.7% of all incident cancers in males with an average annual ASR of 24.4/100,000 people. The incidence of lung cancer was observed to dramatically decline from 1998 to 2014. The lowest ASR (12.9/100,000) was reported in 2009 and the highest (36.7/100,000) in 1998. This could be due to the stringent tobacco control and preventive anti-smoking measures led by government and non-government bodies during this period.⁵ On an average, incidence begins at 30 years of age and was found to increase sharply with age, with the highest rates observed in males over 75 years of age (Figure 13 and Figure 14).

COLORECTAL CANCER

Colorectal cancer accounted for 11.5% of all incident cancers in males with an average annual ASR of 15.0/100,000 people. The trend of colorectal cancer incidence continued to rise steadily over the years; the lowest ASR (10.7/100,000) was reported in 2007 and the highest (21.9/100,000) in 2012. Age-specific incidence among males begins in the 20-25-year age group and steadily rises to peak in the 70-74-year age group (Figure 13 and Figure 14).

PROSTATE CANCER

Prostate cancer was the third most common cancer in Bahraini males and accounted for 8.3% of all incident cancers in Bahraini males, with an average annual ASR of 12.1/100,000 people. Incidence was observed to decline slowly over time. The lowest ASR (4.6/100,000) was reported in 2009 and the highest (19.3/100,000) in 2000. Age-specific incidence of prostate cancer follows a pattern of sharp incline similar to that of lung cancer, but with a delayed start during late adulthood (Figure 13 and Figure 14).

BLADDER CANCER

Bladder cancer accounted for 7.8% of all incident cancers in men, with an average annual ASR of 11.6/100,000 people. Incidence had a tendency to decline during the 17-year period; the lowest ASR (6.4/100,000) was reported in 2009 and the highest (23.6/100,000) in 1999. Although a few childhood cases were reported in 2012, bladder cancer generally appears in early adulthood and directly increases with age after the age of 50 years (Figure 13 and Figure 14).

LEUKEMIA

Leukemia was the fifth most common male cancer and accounted for 6.5% of all incident cancer cases in Bahraini males. The average annual ASR was 7.0/100,000 people. A decreasing ASR trend is observed from 1998 to 2014; the lowest ASR (3.9/100,000) was reported in 2009 and the highest (17.5/100,000) in 1998. Leukemia incidence has an initial peak at infancy and then increases with advancing age after 40 years to reach its highest peak at age 75 and above (Figure 13 and Figure 14).

MOST COMMON CANCERS – 1998-2014

Figure 13 Age-Standardized Incidence Rates of Most Common Cancers among Bahraini Males, 1998-2014





Figure 14 Average Annual Age-Specific Incidence Rates of Most Common Cancers among Bahraini Males, 1998-2014



MOST COMMON CANCERS IN FEMALES

BREAST CANCER

Breast cancer is by far the most common female cancer and accounted for 38.5% of all incident cancer cases in Bahraini women between 1998 and 2014, with an average annual ASR of 50.0/100,000 people. Breast cancer incidence was observed to have an increasing trend over the 17-year period with a dramatic incline after 2009; the lowest ASR (30.8/100,000) was noted in 1998 and the highest (67.7/100,000) in 2013. The implementation of the mammography-based mass breast screening program in 2005 could account for the rise in incidence during 2005-2009.⁵ The age-specific incidence follows a bimodal distribution among Bahraini females with the 1st peak at 45-50 years and the second peak in the 65-69-year age group (Figure 15 and Figure 16).

COLORECTAL CANCER

Colorectal cancer accounted for 7.5% of all incident cancers in females with an average annual ASR of 10.0/100,000 people. Female incidence rates demonstrated a steady increase over the years. The ASR was lowest (5.3/100,000) in 2001 and highest (14.7/100,000) in 2014. Age-specific incidence rates indicate a slow and gradual increase with age, with a peak in the 50-55-year and 70-75-year age groups (Figure 15 and Figure 16).

LUNG CANCER

During the 17-year period, lung cancer accounted for 5.1% of all new female cancers, with an average annual ASR of 9.2/100,000 people. Lung cancer incidence in females also showed a decline, though less dramatic than that in males. The lowest ASR (3.4/100,000) was reported in 2007 and the highest (19.0/100,000) in 1998. As with Bahraini males, lung cancer incidence was found to steadily increase with age, with a sharper incline from 60 years of age (Figure 15 and Figure 16).

THYROID CANCER

Thyroid cancer was the 4th most common female cancer between 1998 and 2014 and accounted for 5% of all incident cancer cases in Bahraini women, with an average annual ASR of 6.1/100,000 people. Incidence of thyroid cancer appeared to decline slowly across the years; the ASR was lowest (2.2/100,000) in 2009 and highest (11.2/100,000) in 2014. Cases were seen in females as young as 15 years of age, and incidence was found to increase with age, with peaks at 60-64 years and at 75 years and over (Figure 15 and Figure 16).

OVARIAN CANCER

Ovarian cancer accounted for 4.9% of all incident cases in females, with an average annual ASR of 6.8/100,000 people. Incidence decreased from 1998 to 2014; the lowest ASR (3.0/100,000) was reported in 2009 and 2007 and the highest (10.6/100,000) in 1998. Ovarian cancer begins in childhood at 5 years of age and incidence was observed to rise at 35-39 years to peak at 70-75 years (Figure 15 and Figure 16).

MOST COMMON CANCERS – 1998-2014

Figure 15 Age-Standardized Incidence Rates of Most Common Cancers among Bahraini Females, 1998-2014





Figure 16 Average Annual Age-Specific Incidence Rates of Most Common Cancers among Bahraini Females, 1998-2014



SUMMARY OF COMMON CANCERS IN BAHRAINIS BY YEAR, 1998-2014

Figure 17 Ten Leading Types of Cancer among Bahrainis, 1998




Figure 18 Ten Leading Types of Cancer among Bahrainis, 1999




Figure 19 Ten Leading Types of Cancer among Bahrainis, 2000




Figure 20 Ten Leading Types of Cancer among Bahrainis, 2001




Figure 21 Ten Leading Types of Cancer among Bahrainis, 2002




Figure 22 Ten Leading Types of Cancer among Bahrainis, 2003




Figure 23 Ten Leading Types of Cancer among Bahrainis, 2004




Figure 24 Ten Leading Types of Cancer among Bahrainis, 2005




Figure 25 Ten Leading Types of Cancer among Bahrainis, 2006




Figure 26 Ten Leading Types of Cancer among Bahrainis, 2007




Figure 27 Ten Leading Types of Cancer among Bahrainis, 2008




Figure 28 Ten Leading Types of Cancer among Bahrainis, 2009




Figure 29 Ten Leading Types of Cancer among Bahrainis, 2010




Figure 30 Ten Leading Types of Cancer among Bahrainis, 2011




Figure 31 Ten Leading Types of Cancer among Bahrainis, 2012





Figure 32 Ten Leading Types of Cancer among Bahrainis, 2013



The 10 leading cancer types among Bahraini males and females during the year 2014 is presented in Figure 36 in the section “Incidence of Most Common Cancers – 2014”.

COMPARISONS OF CANCER INCIDENCE WITH THE GCC STATES


Table 9 presents the most common cancers in males and females among nationals of the GCC states. Lung, colorectal, and prostate cancers among males. Breast, colorectal, and thyroid cancers among females were the most common in almost all GCC countries. Between 1998 and 2009, Bahrain ranked second in cancer incidence after Qatar among the GCC states, with the lowest incidence rates seen in Saudi Arabia (Figure 33).

Table 9 Five Most Common Cancers among Nationals of GCC States

| | Qatar | Bahrain | Kuwait | Oman | UAE | KSA |
|---------------|------------|--------------|--------------|------------|--------------|--------------|
| Male | Lung | Lung | Colorectal | Prostate | Lung | Colorectal |
| | Colorectal | Prostate | Prostate | Colorectal | Colorectal | NHL |
| | Prostate | Colorectal | Leukemia | Stomach | NHL | Leukemia |
| | Liver | Bladder | Bladder | NHL | Prostate | Lung |
| | NHL | NHL | NHL | Leukemia | Leukemia | Liver |
| Female | Breast | Breast | Breast | Breast | Breast | Breast |
| | Colorectal | Colorectal | Colorectal | Thyroid | Thyroid | Thyroid |
| | Thyroid | Thyroid | Thyroid | Colorectal | Colorectal | Colorectal |
| | NHL | Ovary | NHL | Leukemia | Leukemia | Leukemia |
| | Ovary | Corpus uteri | Corpus uteri | NHL | Cervix Uteri | Corpus uteri |

Source: Cancer Incidence in the GCC states, 1998-2009, GCCCP; Bahrain, 2014; Oman 2012; Kuwait 2012; KSA 2011

Figure 33 Average Annual ASRs of all Cancers in the GCC States, 1998-2009




Source: Cancer Incidence in the GCC states, 1998-2009, GCCCP

INTERNATIONAL COMPARISONS OF CANCER

In 2012, Bahrain ranked second in cancer incidence after Qatar among the GCC states, but the incidence is less than the world.

Figure 34 Average Annual ASRs of all Cancers in the World



TREND OF CANCER INCIDENCE

2014

CANCER INCIDENCE, 2014

From January to December 2014, there were 746 Bahraini nationals diagnosed as cancer patients, of which 309 (41.4%) were males and 437 (58.6%) were females. The crude cancer incidence rate for the Bahraini population was 96.4 and 141.1 per 100,000 in males and females, respectively. The world ASR in the year 2014 was 125.9 and 166.2 per 100,000 in males and females, respectively (Table 10).

About half of the cases in Bahraini males occurred in those aged 60 years and above (50.5%), while only 32.7% of cases in Bahraini females occurred in this age group. Overall, 40.1% of new cases occurred in Bahrainis aged over 60 years and over.

Cancer age-specific incidence rates were observed to increase with advancing age in both genders. From early to mid-adulthood, Bahraini females had a higher incidence of cancer compared to males, while after the age of 70, males had a higher incidence of cancer compared to females (Figure 35).

Table 10 Distribution of Incident Cancer Cases among Bahrainis, 2014

| GENDER | FREQUENCY | PERCENTAGE (%) | CRUDE INCIDENCE RATE | AGE-STANDARDIZED RATE (WORLD) |
|--------------|------------|----------------|----------------------|-------------------------------|
| Male | 309 | 41.4 | 96.4 | 125.9 |
| Female | 437 | 58.6 | 141.1 | 166.2 |
| TOTAL | 746 | 100 | | |

Figure 35 Frequency and Age-Specific Incidence Rates of Cancer in Bahrainis, 2014




Table 11 Frequency of Incident Cancer Cases among Bahraini Males, 2014

| SITE | ALL AGES | 0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85+ | % OF TOTAL | ICD (10TH) |
|-----------------------------|------------|-----------|----------|----------|----------|----------|----------|----------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|------------|-------------|
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C00 |
| Tongue | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1.9 | C01-C02 |
| Mouth | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.3 | C03-C06 |
| Salivary glands | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.6 | C07-C08 |
| Tonsil | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C09 |
| Other oropharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C10 |
| Nasopharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C11 |
| Hypopharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C12-C13 |
| Pharynx unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C14 |
| Esophagus | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 1.6 | C15 |
| Stomach | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 0 | 0 | 3 | 1 | 0 | 1 | 2 | 4.2 | C16 |
| Small intestine | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.6 | C17 |
| Colorectum | 34 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 2 | 2 | 4 | 6 | 5 | 3 | 4 | 2 | 1 | 0 | 11.0 | C18-C21 |
| Liver | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 3.6 | C22 |
| Gallbladder etc. | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0.3 | C23-C24 |
| Pancreas | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 3 | 7 | 0 | 1 | 5.2 | C25 |
| Nose, sinuses etc. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C30-C31 |
| Larynx | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 1.6 | C32 |
| Trachea, bronchus, lung | 45 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 4 | 4 | 3 | 7 | 5 | 7 | 9 | 3 | 14.6 | C33-C34 |
| Other thoracic organs | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.6 | C37-C38 |
| Bone | 7 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2.3 | C40-C41 |
| Melanoma of skin | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0.3 | C43 |
| Other skin | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1.3 | C44 |
| Mesothelioma | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0.3 | C45 |
| Kaposi sarcoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C46 |
| Connective, soft tissue | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1.0 | C47-C49 |
| Breast | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1.0 | C50 |
| Penis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C60 |
| Prostate | 29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 7 | 7 | 5 | 1 | 0 | 4 | 9.4 | C61 |
| Testis | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.6 | C62 |
| Other male genital organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C63 |
| Kidney, ureters etc. | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 0 | 1 | 5 | 2 | 0 | 0 | 0 | 0 | 0 | 4.5 | C64-C66;C68 |
| Bladder | 22 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 2 | 3 | 5 | 7.1 | C67 |
| Eye | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C69 |
| Brain, nervous system | 14 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 4 | 1 | 2 | 1 | 0 | 0 | 1 | 0 | 4.5 | C70-C72 |
| Thyroid | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.3 | C73 |
| Adrenal gland | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.3 | C74 |
| Other Endocrine glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C75 |
| Hodgkin's disease | 7 | 0 | 2 | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.3 | C81 |
| Non-Hodgkin's lymphoma | 23 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 3 | 5 | 2 | 1 | 2 | 1 | 1 | 1 | 7.4 | C82-C85;C96 |
| Immunoproliferative disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C88 |
| Multiple Myeloma | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 1.6 | C90 |
| Lymphoid leukemia | 9 | 4 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.9 | C91 |
| Myeloid leukemia | 6 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.9 | C92-C94 |
| Leukemia unspecified | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.3 | C95 |
| Other & unspecified | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 2 | 0 | 1 | 0 | 3.2 | Other |
| TOTAL | 309 | 11 | 4 | 4 | 6 | 4 | 4 | 9 | 7 | 10 | 19 | 37 | 38 | 34 | 37 | 24 | 27 | 18 | 16 | 100 | |

Table 12 Frequency of Incident Cancer Cases among Bahraini Females, 2014

| SITE | ALL AGES | 0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85+ | % OF TOTAL | ICD (10TH) |
|-----------------------------|------------|----------|----------|----------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|----------|-----------|--------------|--------------|
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C00 |
| Tongue | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | C01-C02 |
| Mouth | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | C03-C06 |
| Salivary glands | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0.7 | C07-C08 |
| Tonsil | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C09 |
| Other oropharynx | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | C10 |
| Nasopharynx | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0.2 | C11 |
| Hypopharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C12-C13 |
| Pharynx unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C14 |
| Esophagus | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0.7 | C15 |
| Stomach | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0.9 | C16 |
| Small intestine | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0.5 | C17 |
| Colorectum | 38 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 | 6 | 5 | 8 | 5 | 3 | 2 | 3 | 0 | 0 | 8.7 | C18-C21 |
| Liver | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 2 | 1 | 1 | 2.1 | C22 |
| Gallbladder etc. | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0.7 | C23-C24 |
| Pancreas | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1.1 | C25 |
| Nose, sinuses etc. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C30-C31 |
| Larynx | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.2 | C32 |
| Trachea, bronchus, lung | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 3 | 0 | 2 | 2 | 0 | 2 | 3.2 | C33-C34 |
| Other thoracic organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C37-C38 |
| Bone | 5 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1.1 | C40-C41 |
| Melanoma of skin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C43 |
| Other skin | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0.7 | C44 |
| Mesothelioma | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0.2 | C45 |
| Kaposi sarcoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C46 |
| Connective, soft tissue | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | C47;C49 |
| Breast | 175 | 0 | 0 | 0 | 0 | 1 | 2 | 7 | 11 | 17 | 42 | 28 | 20 | 19 | 13 | 4 | 8 | 2 | 1 | 40.0 | C50 |
| Cervix Uteri | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2.1 | C53 |
| Corpus Uteri | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 4 | 3 | 0 | 3 | 2 | 0 | 0 | 0 | 3.9 | C54 |
| Uterus unspecified | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 1.1 | C55 |
| Ovary | 27 | 0 | 0 | 1 | 0 | 0 | 3 | 1 | 1 | 0 | 5 | 4 | 5 | 2 | 0 | 3 | 0 | 1 | 1 | 6.2 | C56 |
| Other female genital organs | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 1.4 | C51-C52; C57 |
| Placenta | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C58 |
| Kidney, ureters etc. | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0.9 | C64-C66;C68 |
| Bladder | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1.8 | C67 |
| Eye | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C69 |
| Brain, nervous system | 8 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1.8 | C70-C72 |
| Thyroid | 32 | 0 | 0 | 0 | 0 | 2 | 4 | 1 | 5 | 3 | 6 | 3 | 2 | 2 | 1 | 1 | 2 | 0 | 0 | 7.3 | C73 |
| Adrenal gland | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | C74 |
| Other endocrine glands | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | C75 |
| Hodgkin's disease | 7 | 0 | 0 | 1 | 0 | 3 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1.6 | C81 |
| Non-Hodgkin's lymphoma | 18 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 2 | 1 | 0 | 1 | 4 | 1 | 0 | 0 | 3 | 0 | 1 | 4.1 | C82-C85;C96 |
| Immunoproliferative disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C88 |
| Multiple Myeloma | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0.5 | C90 |
| Lymphoid leukemia | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | C91 |
| Myeloid leukemia | 8 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1.8 | C92-C94 |
| Leukemia unspecified | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0.2 | C95 |
| Other & unspecified | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2.3 | Other |
| TOTAL | 437 | 4 | 6 | 4 | 0 | 10 | 13 | 17 | 28 | 33 | 72 | 57 | 50 | 48 | 30 | 21 | 26 | 8 | 10 | 100.0 | |

Table 13 Incidence Rates of Cancers in Bahraini Males, 2014

| SITE | ALL AGES | 0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85+ | CRUDE RATE | ASR World | ICD (10TH) |
|-----------------------------|------------|------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|------------|------------|------------|------------|------------|------------|-------------|-------------|-------------|-------------|--------------|-------------|
| Lip | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C00 |
| Tongue | 6 | - | - | - | - | - | - | - | - | - | - | 12.7 | 7.8 | 10.4 | 19.4 | - | - | 78.1 | - | 1.9 | 2.3 | C01-C02 |
| Mouth | 1 | - | - | - | - | - | - | - | - | - | - | - | 7.8 | - | - | - | - | - | - | 0.3 | 0.3 | C03-C06 |
| Salivary glands | 2 | - | - | - | - | - | - | - | - | - | 5.9 | 6.4 | - | - | - | - | - | - | - | 0.6 | 0.7 | C07-C08 |
| Tonsil | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C09 |
| Other oropharynx | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C10 |
| Nasopharynx | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C11 |
| Hypopharynx | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C12-C13 |
| Pharynx unspecified | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C14 |
| Esophagus | 5 | - | - | - | - | - | - | - | - | - | 5.9 | - | 7.8 | - | 38.9 | - | 45.1 | - | - | 1.6 | 2.3 | C15 |
| Stomach | 13 | - | - | - | - | - | - | - | 4.8 | - | 11.8 | 19.1 | - | - | 58.3 | 28.5 | - | 78.1 | 230.3 | 4.1 | 5.8 | C16 |
| Small intestine | 2 | - | - | - | - | - | - | - | 4.8 | - | 5.9 | - | - | - | - | - | - | - | - | 0.6 | 0.6 | C17 |
| Colorectum | 34 | - | - | - | - | 3.3 | 3.7 | 8.4 | 4.8 | 12.2 | 11.8 | 25.4 | 46.9 | 52 | 58.3 | 113.9 | 90.1 | 78.1 | - | 10.5 | 13.3 | C18-C21 |
| Liver | 11 | - | - | - | - | - | - | - | - | - | 17.6 | 25.5 | 15.6 | - | 38.9 | - | - | - | - | 3.4 | 4.1 | C22 |
| Gallbladder etc. | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.4 | - | - | - | - | 0.3 | 0.6 | C23-C24 |
| Pancreas | 16 | - | - | - | - | - | - | - | - | - | - | 12.7 | 15.6 | 10.4 | - | 85.4 | 315.4 | - | 115.2 | 5 | 7.1 | C25 |
| Nose, sinuses etc. | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C30-C31 |
| Larynx | 5 | - | - | - | - | - | - | - | - | - | - | 6.4 | 15.6 | - | 19.4 | - | 45.1 | - | - | 1.6 | 2 | C32 |
| Trachea, bronchus, lung | 45 | 2.7 | - | - | - | - | - | 4.2 | - | - | 5.9 | 25.5 | 31.3 | 31.2 | 136.1 | 142.3 | 315.4 | 702.5 | 345.5 | 14 | 20 | C33-C34 |
| Other thoracic organs | 2 | - | - | - | - | - | - | - | - | - | - | 12.7 | - | - | - | - | - | - | - | 0.6 | 0.6 | C37-C38 |
| Bone | 7 | 2.7 | - | 3.2 | 3.2 | - | - | - | - | - | - | 12.7 | - | 10.4 | - | - | 45.1 | - | - | 2.2 | 2.4 | C40-C41 |
| Melanoma of skin | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.1 | - | - | 0.3 | 0.5 | C43 |
| Other skin | 4 | - | - | - | - | - | 3.7 | - | - | - | 5.9 | - | - | 10.4 | - | - | 45.1 | - | - | 1.2 | 1.5 | C44 |
| Mesothelioma | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.1 | - | - | 0.3 | 0.5 | C45 |
| Kaposi sarcoma | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C46 |
| Connective, soft tissue | 3 | - | - | - | - | - | - | - | - | - | - | - | - | 10.4 | 19.4 | 28.5 | - | - | - | 0.9 | 1.6 | C47-C49 |
| Breast | 3 | - | - | - | - | - | - | - | 4.8 | 6.1 | - | - | - | - | - | - | 45.1 | - | - | 0.9 | 1.1 | C50 |
| Penis | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C60 |
| Prostate | 29 | - | - | - | - | - | - | - | - | - | - | 6.4 | 31.3 | 72.9 | 136.1 | 142.3 | 45.1 | - | 460.6 | 9 | 14.2 | C61 |
| Testis | 2 | - | - | - | - | 3.3 | - | - | - | 6.1 | - | - | - | - | - | - | - | - | - | 0.6 | 0.6 | C62 |
| Other male genital organs | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C63 |
| Kidney, ureters etc. | 14 | - | - | - | - | - | - | 4.2 | 4.8 | 24.2 | - | 6.4 | 39.1 | 20.8 | - | - | - | - | - | 4.4 | 4.7 | C64-C66;C68 |
| Bladder | 22 | - | - | - | - | - | - | 4.2 | - | 6.1 | 5.9 | 6.4 | 7.8 | 31.2 | 58.3 | 28.5 | 90.1 | 234.2 | 575.8 | 6.9 | 10.1 | C67 |
| Eye | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C69 |
| Brain, nervous system | 14 | 5.4 | - | - | 3.2 | - | - | 4.2 | - | - | 5.9 | 25.5 | 7.8 | 20.8 | 19.4 | - | - | 78.1 | - | 4.4 | 4.9 | C70-C72 |
| Thyroid | 4 | - | - | - | 3.2 | - | - | - | - | - | 11.8 | 6.4 | - | - | - | - | - | - | - | 1.2 | 1.3 | C73 |
| Adrenal gland | 1 | - | 2.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.3 | 0.3 | C74 |
| Other endocrine glands | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C75 |
| Hodgkin's disease | 7 | - | 5.8 | 3.2 | - | - | - | 8.4 | - | 6.1 | 5.9 | - | - | - | - | - | - | - | - | 2.2 | 2.1 | C81 |
| Non-Hodgkin's lymphoma | 23 | 2.7 | - | 6.3 | - | 3.3 | - | 4.2 | 4.8 | - | 5.9 | 19.1 | 39.1 | 20.8 | 19.4 | 56.9 | 45.1 | 78.1 | 115.2 | 7.2 | 8.5 | C82-C85;C96 |
| Immunoproliferative disease | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C88 |
| Multiple myeloma | 5 | - | - | - | - | - | - | - | - | - | - | - | 7.8 | 31.2 | 19.4 | - | - | - | - | 1.6 | 2.1 | C90 |
| Lymphoid leukemia | 9 | 10.7 | 2.9 | - | 6.4 | 3.3 | 3.7 | - | - | - | - | - | - | - | - | - | - | - | - | 2.8 | 2.7 | C91 |
| Myeloid leukemia | 6 | 2.7 | - | - | 3.2 | - | 3.7 | - | 4.8 | - | 5.9 | 6.4 | - | - | - | - | - | - | - | 1.9 | 1.9 | C92-C94 |
| Leukemia unspecified | 1 | 2.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.3 | 0.3 | C95 |
| Other & unspecified | 10 | - | - | - | - | - | - | - | - | - | - | - | 15.6 | 20.8 | 58.3 | 56.9 | - | 78.1 | - | 3.1 | 4.7 | Other |
| TOTAL | 309 | | 12 | 13 | 19 | 13 | 15 | 38 | 33 | 61 | 112 | 236 | 297 | 354 | 719 | 683 | 1217 | 1405 | 1842 | 96.4 | 125.9 | |

Table 14 Incidence Rates of Cancer in Bahraini Females, 2014

| SITE | ALL AGES | 0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85+ | Crude Rate | ASR Rate | ICD (10TH) |
|-----------------------------|----------|-----|-----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|------------|----------|-------------|
| Lip | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C00 |
| Tongue | 1 | - | - | - | - | - | - | - | - | - | - | 6.2 | - | - | - | - | - | - | - | 0.3 | 0.3 | C01-C02 |
| Mouth | 1 | - | - | - | - | - | - | - | - | - | - | - | 7.8 | - | - | - | - | - | - | 0.3 | 0.3 | C03-C06 |
| Salivary glands | 3 | - | - | - | - | 3.5 | 3.8 | - | - | - | - | - | - | - | 21 | - | - | - | - | 1 | 1.2 | C07-C08 |
| Tonsil | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C09 |
| Other oropharynx | 1 | - | - | - | - | - | - | 4.4 | - | - | - | - | - | - | - | - | - | - | - | 0.3 | 0.3 | C10 |
| Nasopharynx | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.4 | - | - | 0.3 | 0.4 | C11 |
| Hypopharynx | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C12-C13 |
| Pharynx unspecified | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C14 |
| Esophagus | 3 | - | - | - | - | - | - | - | - | - | - | - | - | 12.6 | 21 | 26.6 | - | - | - | 1 | 1.7 | C15 |
| Stomach | 4 | - | - | - | - | - | - | 4.4 | - | - | 5.6 | - | - | - | 21 | 26.6 | - | - | - | 1.3 | 1.8 | C16 |
| Small intestine | 2 | - | - | - | - | - | - | - | - | - | - | - | 7.8 | - | 21 | - | - | - | - | 0.6 | 0.9 | C17 |
| Colorectum | 38 | - | - | - | - | - | - | 8.8 | 5 | 18.3 | 33.6 | 31 | 62.7 | 63.1 | 63 | 53.2 | 118.1 | - | - | 12.2 | 14.7 | C18 |
| Liver | 9 | - | - | - | - | - | - | - | 5 | - | 5.6 | - | - | 25.2 | - | 26.6 | 78.7 | 68.2 | 106.3 | 2.9 | 3.8 | C22 |
| Gallbladder etc. | 3 | - | - | - | - | - | - | - | - | - | 5.6 | - | - | 12.6 | - | - | - | 68.2 | - | 1 | 1.2 | C23-C24 |
| Pancreas | 5 | - | - | - | - | - | - | - | - | - | - | 6.2 | 7.8 | 12.6 | - | - | 39.4 | 68.2 | - | 1.6 | 1.9 | C25 |
| Nose, sinuses etc. | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C30-C31 |
| Larynx | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 106.3 | 0.3 | 0.5 | C32 |
| Trachea, bronchus, lung | 14 | - | - | - | - | - | - | - | 6.1 | 5.6 | 12.4 | 7.8 | 37.8 | - | 53.2 | 78.7 | - | 212.7 | 4.5 | 6.1 | C33-C34 | |
| Other Thoracic organs | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C37-C38 |
| Bone | 5 | - | 3 | - | - | - | - | 4.4 | - | 6.1 | 5.6 | - | - | - | - | - | 39.4 | - | - | 1.6 | 1.7 | C40-C41 |
| Melanoma of skin | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C43 |
| Other skin | 3 | - | - | - | - | - | - | - | 5 | 6.1 | - | - | - | - | - | - | - | 68.2 | - | 1 | 1 | C44 |
| Mesothelioma | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.6 | - | - | - | 0.3 | 0.5 | C45 |
| Kaposi sarcoma | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C46 |
| Connective, soft tissue | 1 | - | - | - | - | - | - | - | - | - | 5.6 | - | - | - | - | - | - | - | - | 0.3 | 0.3 | C47-C49 |
| Breast | 175 | - | - | - | 3.5 | 7.7 | 30.7 | 54.6 | 104 | 235.4 | 173.3 | 156.8 | 239.7 | 273.2 | 106.3 | 314.9 | 136.4 | 106.3 | 56.5 | 65.6 | C50 | |
| Cervix Uteri | 9 | - | - | - | - | - | - | - | 14.9 | 12.2 | 11.2 | 6.2 | - | 12.6 | - | - | - | - | - | 2.9 | 3.1 | C53 |
| Corpus Uteri | 17 | - | - | - | - | - | - | - | 9.9 | - | 16.8 | 24.8 | 23.5 | - | 63.1 | 53.2 | - | - | - | 5.5 | 6.7 | C54 |
| Uterus unspecified | 5 | - | - | - | - | - | - | - | - | - | - | 6.2 | - | 37.8 | - | - | 39.4 | - | - | 1.6 | 2.2 | C55 |
| Ovary | 27 | - | - | 3.3 | - | - | 11.5 | 4.4 | 5 | - | 28 | 24.8 | 39.2 | 25.2 | - | 79.8 | - | 68.2 | 106.3 | 8.7 | 9.7 | C56 |
| Other female genital organs | 6 | - | - | - | - | - | - | - | - | - | 11.2 | - | 7.8 | 37.8 | - | - | - | - | - | 1.9 | 2.4 | C51-C52;C57 |
| Placenta | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C58 |
| Kidney, ureters etc. | 4 | 2.8 | 3 | - | - | - | - | - | - | - | - | 6.2 | - | - | 21 | - | - | - | - | 1.3 | 1.6 | C64-C66;C68 |
| Bladder | 8 | - | - | - | - | - | - | - | - | - | - | 6.2 | 7.8 | - | 42 | 26.6 | 39.4 | 68.2 | 106.3 | 2.6 | 3.7 | C67 |
| Eye | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C69 |
| Brain, nervous system | 8 | 2.8 | 3 | 3.3 | - | - | - | 4.4 | - | 6.1 | - | 6.2 | - | 12.6 | 21 | - | - | - | - | 2.6 | 3 | C70-C72 |
| Thyroid | 32 | - | - | - | - | 7 | 15.4 | 4.4 | 24.8 | 18.3 | 33.6 | 18.6 | 15.7 | 25.2 | 21 | 26.6 | 78.7 | - | - | 10.3 | 11.2 | C73 |
| Adrenal gland | 1 | 2.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.3 | 0.3 | C74 |
| Other endocrine glands | 1 | - | - | - | - | - | - | - | 5 | - | - | - | - | - | - | - | - | - | - | 0.3 | 0.3 | C75 |
| Hodgkin's disease | 7 | - | - | 3.3 | - | 10.5 | - | 8.8 | - | - | - | - | - | 12.6 | - | - | - | - | - | 2.3 | 2.2 | C81 |
| Non-Hodgkin's lymphoma | 18 | - | - | - | - | 7 | 11.5 | - | 9.9 | 6.1 | - | 6.2 | 31.4 | 12.6 | - | - | 118.1 | - | 106.3 | 5.8 | 6.2 | C82-C85;C96 |
| Immunoproliferative disease | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | C88 |
| Multiple myeloma | 2 | - | - | - | - | - | - | - | - | 6.1 | - | - | - | - | - | - | 39.4 | - | - | 0.6 | 0.8 | C90 |
| Lymphoid leukemia | 2 | 2.8 | 3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.6 | 0.6 | C91 |
| Myeloid leukemia | 8 | - | 6.1 | 3.3 | - | 3.5 | - | - | - | 12.2 | - | 6.2 | - | - | - | 26.6 | - | - | - | 2.6 | 2.8 | C92-C94 |
| Leukemia unspecified | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.6 | - | - | - | 0.3 | 0.5 | C95 |
| Other & unspecified | 10 | - | - | - | - | - | - | - | - | - | - | 12.4 | 15.7 | 25.2 | 42 | - | - | - | 212.7 | 3.2 | 4.6 | Other |
| Total | 437 | 11 | 18 | 13 | 0 | 35 | 50 | 74 | 139 | 202 | 404 | 353 | 392 | 605 | 631 | 558 | 1024 | 546 | 1063 | 141.1 | 166.2 | |

INCIDENCE OF MOST COMMON CANCERS 2014

MOST COMMON CANCERS IN BAHRAINIS, 2014


In the year 2014, cancers of the breast (178), colorectal (72), lung (59), NHL (41), and thyroid (36) constituted over half of the total cancer burden (51.7%, 386 new cases).

In line with previous years, lung cancer was noted to be the leading malignancy among Bahraini males (45 new cases), followed by cancers of the colorectal (34), prostate (29), NHL (23), and bladder (22). Breast cancer continues to be the most frequent neoplasm in Bahraini women, with 175 new cases reported in 2014, followed by cancers of the colorectal (38), thyroid (32), ovary (27), and NHL (18) (Table 15). Figure 36 presents the 10 leading cancers in Bahraini males and females by ASR.

Table 15 Most Common Cancers among Bahraini Nationals, 2014

| MALES (N = 309) | | | | FEMALES (N = 437) | | | |
|-----------------|-----|------|------|-------------------|-----|------|------|
| Site | No. | % | ASR | Site | No. | % | ASR |
| Lung | 45 | 14.6 | 20.0 | Breast | 175 | 40.0 | 65.6 |
| Colorectal | 34 | 11.0 | 13.3 | Colorectal | 38 | 8.7 | 14.7 |
| Prostate | 29 | 9.4 | 14.2 | Thyroid | 32 | 7.3 | 11.2 |
| NHL | 23 | 7.4 | 8.5 | Ovary | 27 | 6.2 | 9.7 |
| Bladder | 22 | 7.1 | 10.1 | NHL | 18 | 4.1 | 6.2 |
| Leukemia | 16 | 5.2 | 4.9 | Corpus uteri | 17 | 3.9 | 6.7 |
| Pancreas | 16 | 5.2 | 7.1 | Lung | 14 | 3.2 | 6.1 |
| Kidney | 14 | 4.5 | 4.7 | Leukemia | 11 | 2.5 | 3.9 |
| Brain & CNS | 14 | 4.5 | 4.9 | Unspecified | 10 | 2.3 | 4.6 |
| Stomach | 13 | 4.2 | 5.8 | Liver | 9 | 2.1 | 3.8 |

Figure 36 Ten Leading Types of Cancer among Bahrainis by ASR, 2014



Trends of age-specific incidence rates for the 5 common cancers indicate wide gaps between the leading cancer and other cancers at 70 years and above in Bahraini males and from early adulthood in females (Figure 37 and Figure 38).

Figure 37 Age-Specific Incidence of Common Cancers in Bahraini Males, 2014





Figure 38 Age-Specific Incidence of Common Cancers in Bahraini Females, 2014



BREAST

Breast cancer was by far the most common cancer among Bahrainis in 2014, accounting for 40.0% of all new cases of cancer in females and 23.9% of all new cancer cases overall.

Between January and December 2014, there were 178 new cases of breast cancer reported in Bahrain: 175 in women and only 3 in men. The world ASR for breast cancer in Bahraini women was 65.6 per 100,000 females (Table 15 and Figure 36).

Female breast cancer incidence is strongly related to age, with the highest incidence rates being observed in older women. The trend of age-specific incidence rates follows a multimodal distribution, with the highest peaks observed at 45-49, 65-69, and 75-79-year age groups (Figure 39). The peaks may be partly explained by the impact of screening for breast cancer in women aged 40 and over.

Infiltrating ductal carcinoma was the most frequent histopathological type accounting for 78% of all breast cancers, Figure 40.

Figure 39 Age-Specific Incidence Rates for Breast Cancer in Bahraini Females, 2014





Figure 40 Morphology of Breast Cancer in Bahraini Females, 2014



*Not otherwise specified

COLORECTUM

Colorectal cancer is the 2nd most common cancer in Bahrain in 2014, accounting for 9.7% of all new cases (11% of all male cases and 8.7% of all female cases).

Between January and December 2014, there were 72 new cases of colorectal cancer collected by the Bahrain Cancer Registry: 34 (47.2%) in men and 38 (52.8%) in women. The total world ASR for colorectal cancer in the Bahraini population was 14.0 per 100,000 people. The world ASRs by gender were 13.3 cases/100,000 Bahraini males and 14.7 cases/100,000 Bahraini females (Table 16).

In 2014, over 70% of colorectal cancer cases were diagnosed in people over 50 years and incidence rates were higher in females. Age-specific incidence begin between 15-25 years and the rates increase sharply from around age 35 to peak at 70-74 years in males and at 75-79 years in females. (Figure 41).

Adenocarcinomas were the most frequent histopathological type, accounting for 83% of all colorectal cancers (Figure 42).

Table 16 Gender Distribution of Colorectal Cancer in Bahrainis, 2014

| GENDER | FREQUENCY | CRUDE INCIDENCE RATE | AGE-STANDARDIZED RATE (WORLD) |
|--------|-----------|----------------------|-------------------------------|
| Male | 34 | 10.5 | 13.3 |
| Female | 38 | 12.2 | 14.7 |

Figure 41 Age-Specific Incidence Rates for Colorectal Cancer in Bahrainis, 2014





Figure 42 Morphology of Colorectal Cancer in Bahrainis, 2014



*Not otherwise specified

LUNG

Lung cancer is the 3rd most common cancer in Bahrain in 2014, accounting for 7.9% of all new cancer cases. It is also the most common cancer in males (14.6% of all male cases).

Between January and December 2014, there were 59 new cases of lung cancer reported in Bahrain: 45 (76.3%) in men and 14 (23.7%) in women. The total world ASR in the Bahraini population was 12.9 per 100,000 people. The world ASRs by gender were 20.0 cases/100,000 Bahraini males and 6.1 cases/100,000 Bahraini females (Table 17).

In males, age-specific incidence rates rose steadily from around age 45 to age 65-79, followed by a steep incline to peak in the 80-84-year age group, and then fall sharply from age 85 onwards. The female incidence rates, on the other hand, show a gradual rise to peak in the 85+ age group. Incidence rates are similar for Bahraini men and women until their 60s, but thereafter, the male rates are significantly higher than those in females, and this gap widens with increasing age (Figure 43).

Adenocarcinomas and squamous cell carcinomas were the most frequent histopathological types, accounting for 41% and 25% of all lung cancers, respectively (Figure 44).

Table 17 Gender Distribution of Lung Cancer in Bahrainis, 2014

| GENDER | FREQUENCY | CRUDE INCIDENCE RATE | AGE-STANDARDIZED RATE (WORLD) |
|--------|-----------|----------------------|-------------------------------|
| Male | 45 | 14.0 | 20.0 |
| Female | 14 | 4.5 | 6.1 |

Figure 43 Age-Specific Incidence Rates for Lung Cancer in Bahrainis, 2014





Figure 44 Morphology of Lung Cancer in Bahrainis, 2014



*Not otherwise specified

NON-HODGKIN'S LYMPHOMA

Non-Hodgkin's Lymphoma is the 4th most common cancer in Bahrain (2014), accounting for 5.5% of all new cancer cases. NHL is also the 4th most common cancer among Bahraini men, accounting for 7.4% of all new cases in males. Among Bahraini women, NHL is the 5th most common, accounting for 4.1% of all new cases in females.

Between January and December 2014, 41 cases of NHL were registered in Bahrain: 23 (56.1%) in men and 18 (43.9%) in women. The total world ASR in the Bahraini population was 7.4 per 100,000 people. The world ASRs by gender were 8.5 cases/100,000 Bahraini males and 6.2 cases/100,000 Bahraini females (Table 18).

While the majority of NHL cases were diagnosed in older men and women, around 32% of cases were diagnosed in ages under 40. Age-specific incidence rates begin to rise sharply in both sexes from around age 45 to 50 years, and reach their highest peak in the 85+ age group for men and 75-79-year age group for women, Figure 45.

Malignant lymphomas were the most frequent histopathological type, accounting to 78% of all NHL cases (Figure 46).

Table 18 Gender Distribution of NHL in Bahrainis, 2014

| GENDER | FREQUENCY | CRUDE INCIDENCE RATE | AGE-STANDARDIZED RATE (WORLD) |
|--------|-----------|----------------------|-------------------------------|
| Male | 23 | 7.2 | 8.5 |
| Female | 18 | 5.8 | 6.2 |

Figure 45 Age-Specific Incidence Rates for NHL in Bahrainis, 2014






Figure 46 Morphology of NHL in Bahrainis, 2014



*Not otherwise specified

THYROID

Thyroid cancer is the 5th most common cancer in Bahrain (2014), accounting for 4.8% of all new cancer cases. Among Bahraini women, it is the 3rd most common cancer (7.3% of all female cases).

Between January and December 2014, there were 36 cases of thyroid cancer registered in Bahrain: 32 (88.9%) in women and only 4 (11.1%) in men, with a female to male ratio of 8:1. The total world ASR in the Bahraini population was 6.2 per 100,000 people. The world ASRs by gender were 1.3 cases/100,000 Bahraini males and 11.2 cases/100,000 Bahraini females (Table 19).

In Bahraini females, age-specific rates rise steadily from around age 30 with a sharp peak at 80-84 years and then fall at 85 years and above (Figure 47).

Papillary carcinomas were the most frequent histopathological type, accounting for 77.8% of all thyroid cancers (75% in females, 100% in males) (Figure 48).

Table 19 Gender Distribution of Thyroid Cancer in Bahrainis, 2014

| GENDER | FREQUENCY | CRUDE INCIDENCE RATE | AGE-STANDARDIZED RATE (WORLD) |
|--------|-----------|----------------------|-------------------------------|
| Male | 4 | 1.2 | 1.3 |
| Female | 32 | 10.3 | 11.2 |

Figure 47 Age-Specific Incidence Rates for Thyroid Cancer in Bahrainis, 2014





Figure 48 Morphology of Thyroid Cancer in Bahraini Females, 2014



*Not otherwise specified

BLADDER

Bladder cancer is the 6th most common cancer in Bahrain (2014), accounting for 4% of all new cancer cases. Among Bahraini men, it is the 5th most common cancer (7.1% of all male cases).

Between January and December 2014, 30 cases of bladder cancer were reported: 22 (73.3%) in men and 8 (26.7%) in women. The total world ASR in the Bahraini population was 6.9 per 100,000 people. The world ASRs by gender were 10.1 cases/100,000 Bahraini males and 3.7 cases/100,000 Bahraini females (Table 20).

In the year 2014, about 67% of bladder cancer cases were diagnosed in men and women aged 65 years and above, and 83% were diagnosed in ages 55 years and above.

Age-specific incidence rates begin to rise from around age 55-65 years in both males and females. However, from age 70 until 85+, male incidence rates rise more sharply than female rates. For both sexes, incidence rates reach their highest peak in the 85+ age group.

Transitional cell carcinomas and papillary transitional cell carcinomas were the most frequent histopathological types, accounting for 57% and 30% of all bladder cancers, respectively (Figure 50).

Table 20 Gender Distribution of Bladder Cancer in Bahrainis, 2014

| GENDER | FREQUENCY | CRUDE INCIDENCE RATE | AGE-STANDARDIZED RATE (WORLD) |
|--------|-----------|----------------------|-------------------------------|
| Male | 22 | 6.9 | 10.1 |
| Female | 8 | 2.6 | 3.7 |

Figure 49 Age-Specific Incidence Rates of Bladder Cancer in Bahrainis, 2014





Figure 50 Morphology of Bladder Cancer in Bahrainis, 2014



*Not otherwise specified

PROSTATE

Prostate cancer is the 7th most common cancer in Bahrain (2014), accounting for 3.9% of all new cancer cases. It is also the 3rd most common cancer among Bahraini men (9.4% of all male cases).

Between January and December 2014, there were 29 cases of prostate cancer registered in Bahrain. The world ASR in Bahraini men was 14.2 cases/100,000 (Table 15 and Figure 36).

In 2014, nearly 83% of prostate cancer cases were diagnosed in Bahraini men aged 60 years and older. Age-specific incidence was observed to rise from around age 50-54, with the highest rates in those aged over 85 years. (Figure 51).

Adenocarcinomas were the most frequent histopathological type, accounting for 80% of all prostate cancers (Figure 52).

Figure 51 Age-Specific Incidence Rates for Prostate Cancer in Bahraini Males, 2014





Figure 52 Morphology of Prostate Cancer in Bahraini Males, 2014



*Not otherwise specified

OVARY

Ovarian cancer is the 8th most common cancer in Bahrain (2014), accounting for 3.6% of all new cancer cases, and the 4th most common cancer in Bahraini females (6.2% of the female total).

Between January and December 2014, there were 27 new cases of ovarian cancer reported in Bahrain, with a world ASR of 9.7 per 100,000 Bahraini females (Table 15 and Figure 36).

Ovarian cancer incidence is strongly related to age, with the highest incidence being in older women. In 2014, over 77% of cases were diagnosed in females aged over 40 years. Incidence is observed at as early as 10 years of age. Age-specific incidence rates rise sharply at around age 40-44 years to reach their highest peak at 85 years and above (Figure 53).

Adenocarcinomas were the most frequent histopathological types accounting for 30% of all ovarian cancers, followed by mucinous cystadenocarcinomas (11%) and unspecified carcinomas (11%) (Figure 54).

Figure 53 Age-Specific Incidence Rates for Ovarian Cancer in Bahraini Females, 2014





Figure 54 Morphology of Ovarian Cancer in Bahraini Females, 2014



BRAIN AND CENTRAL NERVOUS SYSTEM

Brain and CNS tumors are the 9th most common cancer in Bahrain (2014), and account for 2.9% of all new cases. They are also the 8th most common cancer in Bahraini males (4.5% of the male total).

In 2014, 22 new cases of brain tumors were reported: 14 (63.6%) male and 8 (36.4%) female. The total world ASR in the Bahraini population was 4.0 per 100,000 people. The world ASRs by gender were 4.9 cases/100,000 Bahraini males and 3.0 cases/100,000 Bahraini females (Table 21).

In contrast to most cancer types, these tumors occur relatively frequently across all age groups, including children and teenagers and young adults. In 2014, incidence rates remain relatively stable from infancy to around age 40, before increasing more sharply (particularly in males) to peak at 80-84 years in males and 65-69 years in females (Figure 55).

Glioblastomas were the most frequent histopathological type, accounting for 33% of all brain and CNS tumors, followed by astrocytomas (14% of the total) (Figure 56).

Table 21 Gender Distribution of Brain and CNS Tumors in Bahrainis, 2014

| GENDER | FREQUENCY | CRUDE INCIDENCE RATE | AGE-STANDARDIZED RATE (WORLD) |
|--------|-----------|----------------------|-------------------------------|
| Male | 14 | 4.4 | 4.9 |
| Female | 8 | 2.6 | 3.0 |

Figure 55 Age-Specific Incidence Rates for Brain and CNS tumors in Bahrainis, 2014





Figure 56 Morphology of Brain and CNS Tumors in Bahrain, 2014



*Not otherwise specified

PANCREAS

Pancreatic cancer is the 10th most common cancer in Bahrain (2014), accounting for 2.8% of all new cancer cases, and the 6th most common cancer in Bahraini men (5.2% of the male total).

In 2014, 21 Bahraini people had a diagnosis of pancreatic cancer: 16 were male (76.2%) and 5 female (23.8%). The total world ASR in the Bahraini population was 4.4 per 100,000 people. The world ASRs by gender were 7.1 cases/100,000 Bahraini males and 1.9 cases/100,000 Bahraini females (Table 22).

The incidence of pancreatic cancer is strongly related to age, with the highest incidence rates being in older men and women. In 2014, over 47% of cases were diagnosed in men and women aged 75 and above, and 100% were diagnosed in those aged 50 and above. Age-specific incidence rates in men rise from around age 50-54, peak sharply in the 75-79 age group, then decline, and subsequently rise again to peak in the 85+ age group. In women, incidence also begins at 50-54 years and peak at 80-84 years. Incidence rates are higher for men than for women, and this gap is widest at ages 75-79 (Figure 57).

Adenocarcinomas were the most frequent histopathological type, accounting for 52% of all pancreatic cancer cases (Figure 58).

Table 22 Gender Distribution of Pancreatic Cancer in Bahrainis, 2014

| GENDER | FREQUENCY | CRUDE INCIDENCE RATE | AGE-STANDARDIZED RATE (WORLD) |
|--------|-----------|----------------------|-------------------------------|
| Male | 16 | 5.0 | 7.1 |
| Female | 5 | 1.6 | 1.9 |

Figure 57 Age-Specific Incidence Rates for Pancreatic Cancer in Bahrainis, 2014





Figure 58 Morphology of Pancreatic Cancer in Bahrainis, 2014



*Not otherwise specified

CHILDHOOD CANCER

1998 – 2014

TRENDS OF CHILDHOOD CANCER INCIDENCE, 1998-2014

Of the 8,013 cases of cancer registered between January 1998 and December 2014, 358 cases were reported in children aged 0-14 years, constituting approximately 4.5% of the total cancers reported. The average annual frequency of childhood cancers was 21 cases per year. Of these 358 cases in children, 216 (60.3%) were boys and 142 (39.7%) were girls.

The average annual truncated crude incidence cancer rate was higher among Bahraini boys at 14.2 per 100,000 compared to 9.6 per 100,000 in Bahraini girls. The average annual truncated world ASRs were 14.6 and 9.9 per 100,000 Bahraini boys and girls, respectively (Table 23).

The frequencies and incidence rates of cancers in Bahraini males and females are presented in Table 24 to Table 27.

Overall, leukemia (128 cases), and cancers of the brain and CNS (57 cases), Hodgkin's disease (32 cases), kidney (26 cases), and NHL (26 cases) constituted over 75% of the total childhood cancer burden (269 new cases) during the 17-year period.

Table 23 Distribution of Incident Cancer Cases among Bahraini Children, 1998-2014

| GENDER | FREQUENCY | PERCENTAGE (%) | AVERAGE ANNUAL CRUDE INCIDENCE RATE | AVERAGE ANNUAL ASR (WORLD) |
|--------------|------------|----------------|-------------------------------------|----------------------------|
| Male | 216 | 60.3 | 14.2 | 14.6 |
| Female | 142 | 39.7 | 9.6 | 9.9 |
| TOTAL | 358 | 100 | | |

Over the 17-year period, while the average annual world ASRs for all childhood cancers combined demonstrated a steadily inclining trend in Bahraini boys, the rates appear to be decreasing in girls. For both sexes, the rates dropped significantly in 2007, but began to rise again over the next 7 years. (Figure 59).

Girls had generally lower incidence rates than boys throughout ages 0-14. The average annual age-specific incidence rates indicated a tendency to decline from childhood to pre-adolescence in both sexes. Incidence of cancer was highest among children under the age of 5, with age-specific rates of 17.8 and 13.2 cases per 100,000 boys and girls, respectively (Figure 60).

Table 24 Frequency of Incident Cancer Cases among Bahraini Boys, 1998-2014

| CANCER SITE | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | ICD (10TH) |
|-------------------------|-----------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|----------|-----------|----------|-----------|-----------|-----------|-----------|-----------|--------------|
| Liver | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | C22 |
| Nose, sinuses etc. | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C30-C31 |
| Trachea, bronchus, lung | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | C33-C34 |
| Other thoracic organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | C37-C38 |
| Bone | 0 | 0 | 2 | 1 | 1 | 2 | 0 | 2 | 3 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | C40-C41 |
| Connective, soft tissue | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | C47-C49 |
| Testis | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C62 |
| Kidney, ureters etc | 3 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | C64-C66; C68 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | C67 |
| Eye | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | C69 |
| Brain, nervous system | 1 | 1 | 3 | 3 | 3 | 1 | 4 | 0 | 2 | 2 | 3 | 0 | 2 | 3 | 2 | 3 | 2 | C70-C72 |
| Adrenal gland | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | C74 |
| Other Endocrine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | C75 |
| Hodgkin's disease | 1 | 0 | 1 | 0 | 1 | 2 | 2 | 3 | 0 | 1 | 2 | 2 | 1 | 0 | 3 | 2 | 3 | C81 |
| Non-Hodgkin lymphoma | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 3 | C82-C85;C96 |
| Multiple myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | C90 |
| Lymphoid leukemia | 3 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 0 | 3 | 1 | 3 | 4 | 3 | 3 | 5 | C91 |
| Myeloid leukemia | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 2 | 2 | 1 | 0 | 2 | 2 | 1 | C92-C94 |
| Leukemia unspecified | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 3 | 0 | 2 | 3 | 1 | 1 | 1 | C95 |
| Other & unspecified | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | Other |
| TOTAL | 11 | 8 | 12 | 14 | 11 | 12 | 13 | 12 | 14 | 8 | 16 | 9 | 13 | 14 | 17 | 13 | 19 | |

Table 25 Frequency of Incident Cancer Cases among Bahraini Girls, 1998-2014

| CANCER SITE | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | ICD (10TH) |
|-------------------------|----------|-----------|-----------|----------|----------|----------|-----------|----------|-----------|----------|-----------|----------|----------|----------|----------|-----------|-----------|--------------|
| Colorectum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | C18-C21 |
| Trachea, bronchus, lung | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C33-C34 |
| Bone | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | C40-C41 |
| Connective, soft tissue | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | C47;C49 |
| Ovary | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | C56 |
| Kidney, ureters etc. | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 1 | 4 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | C64-C66; C68 |
| Bladder | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C67 |
| Eye | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | C69 |
| Brain, nervous system | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 3 | 0 | 1 | 1 | 3 | 3 | 1 | 2 | 3 | C70-C72 |
| Adrenal gland | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | C74 |
| Other endocrine glands | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C75 |
| Hodgkin's disease | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | C81 |
| Non-Hodgkin lymphoma | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 1 | 0 | C82-C85;C96 |
| Lymphoid leukemia | 3 | 2 | 5 | 2 | 2 | 0 | 3 | 1 | 0 | 1 | 2 | 2 | 1 | 0 | 0 | 1 | 2 | C91 |
| Myeloid leukemia | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 1 | 3 | C92-C94 |
| Leukemia unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | C95 |
| Other & unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Other |
| TOTAL | 6 | 10 | 10 | 7 | 3 | 5 | 11 | 7 | 18 | 3 | 11 | 7 | 7 | 8 | 5 | 10 | 14 | |

Table 26 World Age-Standardized Incidence Rates of Cancers in Bahraini Boys, 1998-2014

| CANCER SITE | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | ICD (10TH) |
|-------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|--------------|
| Liver | 0.0 | 0.0 | 0.0 | 0.0 | 1.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.1 | 0.0 | C22 |
| Nose, sinuses etc. | 0.0 | 0.0 | 0.0 | 1.3 | 0.0 | 0.0 | 1.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C30-C31 |
| Trachea, bronchus, lung | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 0.0 | 1.0 | C33-C34 |
| Other thoracic organs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C37-C38 |
| Bone | 0.0 | 0.0 | 2.3 | 1.3 | 1.1 | 2.6 | 0.0 | 3.4 | 2.6 | 1.0 | 0.0 | 0.0 | 1.0 | 1.0 | 0.0 | 0.0 | 2.0 | C40-C41 |
| Other skin | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C44 |
| Connective, soft tissue | 0.0 | 0.0 | 0.0 | 1.5 | 0.0 | 1.5 | 0.0 | 0.0 | 1.2 | 0.0 | 0.0 | 0.0 | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 | C47-C49 |
| Testis | 0.0 | 2.8 | 0.0 | 1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C62 |
| Kidney, ureter etc. | 4.5 | 0.0 | 1.0 | 1.5 | 1.5 | 0.0 | 1.2 | 0.0 | 1.2 | 1.4 | 1.8 | 1.2 | 0.0 | 1.2 | 0.0 | 0.0 | 0.0 | C64-C66; C68 |
| Bladder | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.1 | 0.0 | 0.0 | C67 |
| Eye | 0.0 | 0.0 | 1.3 | 0.0 | 0.0 | 0.0 | 1.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 0.0 | 0.0 | 0.0 | C69 |
| Brain, nervous system | 1.3 | 1.6 | 2.9 | 3.8 | 3.7 | 1.2 | 5.2 | 1.1 | 2.1 | 2.1 | 2.6 | 0.0 | 2.2 | 3.0 | 2.0 | 3.2 | 2.1 | C70-C72 |
| Adrenal gland | 0.0 | 1.6 | 0.0 | 2.8 | 0.0 | 0.0 | 1.5 | 0.0 | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.9 | C74 |
| Other Endocrine glands | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | C74 |
| Hodgkin's disease | 1.3 | 0.0 | 1.3 | 0.0 | 1.1 | 2.3 | 2.1 | 5.0 | 0.0 | 1.4 | 1.7 | 2.1 | 1.0 | 0.0 | 3.0 | 1.9 | 2.8 | C81 |
| Non-Hodgkin lymphoma | 0.0 | 1.3 | 0.0 | 0.0 | 0.0 | 2.3 | 1.2 | 3.6 | 0.0 | 0.0 | 1.0 | 1.2 | 1.2 | 1.0 | 1.1 | 0.0 | 2.9 | C82-C85;C96 |
| Multiple myeloma | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 | C90 |
| Lymphoid leukemia | 3.8 | 2.9 | 3.3 | 4.4 | 2.7 | 2.2 | 2.3 | 2.5 | 0.8 | 0.0 | 2.9 | 1.2 | 3.5 | 4.3 | 3.2 | 3.1 | 5.1 | C91 |
| Myeloid leukemia | 1.6 | 1.2 | 0.0 | 1.3 | 1.5 | 0.0 | 0.0 | 0.0 | 2.0 | 1.0 | 1.7 | 2.2 | 1.0 | 0.0 | 2.2 | 2.1 | 1.0 | C92-C94 |
| Leukemia unspecified | 0.0 | 0.0 | 1.3 | 0.0 | 0.0 | 1.2 | 0.0 | 1.4 | 1.8 | 1.1 | 2.6 | 0.0 | 2.3 | 3.3 | 1.1 | 1.1 | 1.0 | C95 |
| Other & unspecified | 2.9 | 0.0 | 0.0 | 0.0 | 1.2 | 1.2 | 0.0 | 0.0 | 0.0 | 1.4 | 0.0 | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | Other |
| TOTAL | 15.0 | 11.1 | 13.1 | 18.9 | 14.7 | 14.4 | 16.7 | 18.2 | 14.1 | 9.0 | 13.9 | 10.4 | 14.2 | 14.8 | 17.9 | 13.4 | 19.3 | |

Table 27 World Age-Standardized Incidence Rates of Cancers in Bahraini Girls, 1998-2014

| CANCER SITE | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | ICD (10TH) |
|-----------------------------|------------|-------------|-------------|------------|------------|------------|-------------|-------------|-------------|------------|-------------|------------|------------|------------|------------|-------------|-------------|--------------|
| Colorectum | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C18-C21 |
| Trachea, bronchus, lung | 0.0 | 1.3 | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C33-C34 |
| Other thoracic organs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C37-C38 |
| Bone | 2.6 | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | 0.0 | 0.9 | 1.3 | 0.0 | 1.0 | 0.0 | 0.0 | 1.0 | C40-C41 |
| Connective, soft tissue | 0.0 | 1.7 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 3.3 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.1 | 3.2 | 0.0 | C47;C49 |
| Ovary | 0.0 | 0.0 | 1.0 | 1.2 | 0.0 | 0.0 | 0.0 | 1.1 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | C56 |
| Kidney, ureter, pelvis etc. | 0.0 | 3.0 | 1.3 | 0.0 | 0.0 | 0.0 | 1.6 | 1.6 | 5.0 | 0.0 | 1.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.1 | C64-C66; C68 |
| Bladder | 0.0 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C67 |
| Eye | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C69 |
| Brain, nervous system | 0.0 | 1.3 | 1.3 | 0.0 | 0.0 | 1.2 | 3.2 | 0.0 | 3.0 | 0.0 | 1.0 | 1.0 | 3.4 | 3.3 | 1.2 | 2.1 | 3.0 | C70-C72 |
| Adrenal gland | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 0.0 | 0.0 | 1.1 | C74 |
| Other endocrine glands | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | C75 |
| Hodgkin's disease | 0.0 | 1.3 | 1.1 | 2.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 2.0 | 1.0 | C81 |
| Non-Hodgkin lymphoma | 0.0 | 0.0 | 0.0 | 1.2 | 0.0 | 2.9 | 2.8 | 0.0 | 0.0 | 1.0 | 0.9 | 0.0 | 0.0 | 2.3 | 0.0 | 1.1 | 0.0 | C82-C85;C96 |
| Lymphoid leukemia | 4.6 | 2.5 | 5.8 | 2.5 | 3.2 | 0.0 | 3.4 | 1.6 | 0.0 | 1.2 | 1.9 | 2.5 | 1.1 | 0.0 | 0.0 | 1.1 | 2.1 | C91 |
| Myeloid leukemia | 1.4 | 1.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.9 | 0.0 | 1.9 | 1.3 | 1.2 | 0.0 | 0.0 | 1.1 | 2.9 | C92-C94 |
| Leukemia unspecified | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 1.6 | 6.1 | 1.0 | 1.0 | 1.0 | 1.2 | 1.2 | 1.1 | 0.0 | 0.0 | C95 |
| Other & unspecified | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 0.9 | 0.0 | 0.0 | 0.0 | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 | Other |
| TOTAL | 8.5 | 14.0 | 11.8 | 9.0 | 4.6 | 7.6 | 14.8 | 10.8 | 18.8 | 3.3 | 10.4 | 8.2 | 8.5 | 8.7 | 5.5 | 10.5 | 13.8 | |

Figure 59 Truncated Age-Standardized Incidence Rates of Cancers among Bahraini Children by Year, 1998-2014





Figure 60 Average Annual Age-Specific Incidence Rates of Cancers among Bahraini Children, 1998-2014




MOST COMMON CANCERS IN BAHRAINI CHILDREN, 1998-2014

Between 1998 and 2014, leukemia was observed to be the leading malignancy in Bahraini boys (76 new cases), followed by brain tumors, Hodgkin’s disease, NHL, and bone cancer. Leukemia was also the most common cancer among Bahraini girls with 52 new cases, followed by cancers of the brain, kidney, NHL, and connective tissue (Table 28 and Figure 61).

Table 28 Most Common Childhood Cancers among Bahraini Nationals, 1998-2014

| MALES (N = 216) | | | | FEMALES (N = 142) | | | |
|-------------------------|-----|------|-----|-------------------------|-----|------|-----|
| Site | No. | % | ASR | Site | No. | % | ASR |
| Leukemia | 76 | 35.2 | 5.0 | Leukemia | 52 | 36.6 | 3.6 |
| Brain & CNS | 35 | 16.2 | 2.4 | Brain & CNS | 22 | 15.5 | 1.5 |
| Hodgkin’s disease | 24 | 11.1 | 1.6 | Kidney | 13 | 9.2 | 1.0 |
| NHL | 16 | 7.4 | 1.0 | NHL | 10 | 7.0 | 0.7 |
| Bone | 16 | 7.4 | 1.1 | Connective, soft tissue | 10 | 7.0 | 0.7 |
| Kidney | 13 | 6.0 | 1.0 | Hodgkin’s disease | 8 | 5.6 | 0.5 |
| Adrenal gland | 7 | 3.2 | 0.5 | Bone | 8 | 5.6 | 0.5 |
| Unspecified | 6 | 2.8 | 0.5 | Ovary | 5 | 3.5 | 0.3 |
| Connective, soft tissue | 4 | 1.9 | 0.3 | Adrenal gland | 4 | 2.8 | 0.3 |
| Testis | 4 | 1.9 | 0.3 | Unspecified | 3 | 2.1 | 0.2 |

Figure 61 Most Common Childhood Cancers among Bahrainis by ASR, 1998-2014



The truncated ASRs and age-specific incidence rates of the 5 common cancers among Bahraini boys and girls are presented in Figure 62 to Figure 65. For both boys and girls, clear gaps were observed between the leading cancer leukemia and other common cancers at most years and at all age groups.

Figure 62 Truncated Age-Standardized Incidence Rates of Most Common Cancers among Bahraini Boys, 1998-2014




Figure 63 Average Annual Age-Specific Incidence Rates of Most Common Cancers among Bahraini Boys, 1998-2014




Figure 64 Truncated Age-Standardized Incidence Rates of Most Common Cancers among Bahraini Girls, 1998-2014





Figure 65 Average Annual Age-Specific Incidence Rates of Most Common Cancers among Bahraini Girls, 1998-2014



INCIDENCE OF CHILDHOOD CANCERS, 2014

Of the 746 new cancer cases reported in Bahrainis during 2014, 33 cases were among children aged 14 years and under (19 boys [57.6%] and 14 girls [42.4%]), constituting 4.4% of the total cancers reported.

The crude incidence rates for childhood cancer in Bahrainis in 2014 were 18.4 and 14.2 per 100,000 in boys and girls, respectively. The truncated world ASR rates for childhood cancer were 19.3 and 13.8 per 100,000 in boys and girls, respectively (Table 29).

Nearly 58% of cases in Bahraini boys occurred at infancy (0-4 years) with the highest incidence rates observed in this age group. Cancer incidence in girls was highest in the 5-9 age group (Figure 66).

Table 29 Distribution of Incident Cancers among Bahraini Children, 2014

| GENDER | FREQUENCY | PERCENTAGE (%) | TRUNCATED CRUDE INCIDENCE RATE | TRUNCATED AGE-STANDARDIZED RATE (WORLD) |
|--------|-----------|----------------|--------------------------------|---|
| Male | 19 | 57.6 | 18.4 | 19.3 |
| Female | 14 | 42.4 | 14.2 | 13.8 |
| TOTAL | 33 | 100 | | |

Figure 66 Frequency and Age-Specific Incidence Rates of Cancer in Bahraini Children, 2014




Table 30 Frequency of Incident Cancer Cases in Bahraini Boys (0-14 years), 2014

| SITE | ALL AGES | 0-4 | 5-9 | 10-14 | % OF TOTAL | ICD (10TH) |
|-------------------------|-----------|-----------|----------|----------|------------|-------------|
| Trachea, bronchus, lung | 1 | 1 | 0 | 0 | 5.3 | C33-C34 |
| Bone | 2 | 1 | 0 | 1 | 10.5 | C40-C41 |
| Brain, nervous system | 2 | 2 | 0 | 0 | 10.5 | C70-C72 |
| Adrenal gland | 1 | 0 | 1 | 0 | 5.3 | C74 |
| Hodgkin's disease | 3 | 0 | 2 | 1 | 15.8 | C81 |
| Non-Hodgkin's lymphoma | 3 | 1 | 0 | 2 | 15.8 | C82-C85;C96 |
| Lymphoid leukemia | 5 | 4 | 1 | 0 | 26.3 | C91 |
| Myeloid leukemia | 1 | 1 | 0 | 0 | 5.3 | C92-C94 |
| Leukemia unspecified | 1 | 1 | 0 | 0 | 5.3 | C95 |
| TOTAL | 19 | 11 | 4 | 4 | 100 | |

Table 31 Frequency of Incident Cancer Cases in Bahraini Girls (0-14 years), 2014

| SITE | ALL AGES | 0-4 | 5-9 | 10-14 | % OF TOTAL | ICD (10TH) |
|-----------------------|-----------|----------|----------|----------|------------|-------------|
| Bone | 1 | 0 | 1 | 0 | 7.1 | C40-C41 |
| Ovary | 1 | 0 | 0 | 1 | 7.1 | C56 |
| Kidney, ureters etc. | 2 | 1 | 1 | 0 | 14.3 | C64-C66;C68 |
| Brain, nervous system | 3 | 1 | 1 | 1 | 21.4 | C70-C72 |
| Adrenal gland | 1 | 1 | 0 | 0 | 7.1 | C74 |
| Hodgkin's disease | 1 | 0 | 0 | 1 | 7.1 | C81 |
| Lymphoid leukemia | 2 | 1 | 1 | 0 | 14.3 | C91 |
| Myeloid leukemia | 3 | 0 | 2 | 1 | 21.4 | C92-C94 |
| TOTAL | 14 | 4 | 6 | 4 | 100 | |

MOST COMMON CANCERS IN BAHRAINI CHILDREN, 2014

Leukemia, brain & CNS tumors, Hodgkin's disease, bone tumors, and NHL were the top 5 cancers among Bahraini children in the year 2014, accounting for 82% of childhood cancer cases. Table 32 presents the top 5 cancers in Bahraini children by gender.

Table 32 Most Common Cancers among Bahraini Children, 2014

| MALES (N = 19) | | | | FEMALES (N = 142) | | | |
|----------------------|-----|------|-----|-------------------|-----|------|-----|
| Site | No. | % | ASR | Site | No. | % | ASR |
| Leukemia | 7 | 36.8 | 7.2 | Leukemia | 5 | 35.7 | 5.0 |
| Hodgkin's disease | 3 | 15.8 | 2.8 | Brain & CNS | 3 | 21.4 | 3.0 |
| Non-Hodgkin lymphoma | 3 | 15.8 | 2.9 | Kidney | 2 | 14.3 | 2.1 |
| Bone | 2 | 10.5 | 2.0 | Hodgkin's disease | 1 | 7.1 | 1.0 |
| Brain & CNS | 2 | 10.5 | 2.1 | Bone | 1 | 7.1 | 1.0 |

CANCER MORTALITY

2014

TRENDS OF CANCER MORTALITY, 2014

In 2014, there were a total of 265 deaths among Bahrainis with cancer as the underlying cause of death, of which 134 (50.6%) were in males and 131 (49.4%) in females (Table 33).

The crude mortality rate indicates that there were approximately 42 deaths from cancer for every 100,000 people among Bahrainis in 2014. The world ASRs by gender were observed to be slightly lower in females than in males (52.9 versus 57.1 per 100,000).

Overall, cancer age-specific mortality rates were observed to increase with advancing age in both genders. During early to mid-adulthood, Bahraini females showed a higher mortality due to cancer compared to males, while after the age of 70, males had higher mortality rates compared to females (Figure 67).

Breast cancer (44 deaths), colorectal cancer (32 deaths), unspecified cancers (26 deaths), lung cancer (24 deaths), and prostate cancer (16 deaths) were the leading cancers responsible for cancer deaths in 2014. Together, these 5 cancer sites represented 53.58% of all deaths from cancer, with breast cancer accounting for 16.6% and colorectal cancer accounting for 12.1% of the total.

Among males, colorectal and lung cancers were the leading cause of cancer mortality, with 21 and 20 deaths in 2014. Prostate cancer (16 deaths), unspecified cancers (13 deaths) and stomach cancer (10 deaths) were the next most common causes of cancer deaths. These leading cancers accounted for nearly 60% of all deaths due to cancer among Bahraini males (Figure 68).

Breast cancer was by far the most common cancer causing death in Bahraini females in 2014 (42 deaths). Unspecified cancers (13 deaths), colorectal cancer (11 deaths), ovarian cancer (10 deaths) and pancreatic cancer (5 deaths) were the next most common causes of cancer deaths. Together, these leading cancers accounted for 62% of all deaths from cancer in Bahraini females (Figure 68).

Table 33 Distribution of Cancer Deaths among Bahrainis by Gender, 2014

| GENDER | FREQUENCY | PERCENTAGE (%) | CRUDE MORTALITY RATE | AGE-STANDARDIZED MORTALITY RATE (WORLD) |
|--------------|------------|----------------|----------------------|---|
| Male | 134 | 50.6 | 41.8 | 57.1 |
| Female | 131 | 49.4 | 42.3 | 52.9 |
| TOTAL | 265 | 100 | | |

Figure 67 Frequency and Age-Specific Rates of Cancer Deaths in Bahrain, 2014





Figure 68 Top Leading Sites of Cancer Mortality among Bahrainis, 2014



CANCER MORTALITY – 2014

Table 34 Frequency of Cancer Deaths among Bahraini Males, 2014

| CANCER SITE | ALL AGE AGES | 0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75+ | % OF TOTAL | ICD (10TH) |
|-------------------------|--------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|-----------|-----------|-----------|-----------|-----------|------------|--------------|
| Tongue | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0.7 | C01-C02 |
| Mouth | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0.7 | C03-C06 |
| Tonsil | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.7 | C09 |
| Esophagus | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1.5 | C15 |
| Stomach | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 1 | 7.5 | C16 |
| Colorectum | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 3 | 1 | 2 | 3 | 2 | 6 | 15.7 | C18-C21 |
| Liver | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 2 | 0 | 0 | 0 | 3.7 | C22 |
| Pancreas | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 2 | 3 | 6.7 | C25 |
| Nose, sinuses etc. | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0.7 | C30-C31 |
| Larynx | 29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0.7 | C32 |
| Trachea, bronchus, lung | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 3 | 2 | 1 | 12 | 14.9 | C33-C34 |
| Other thoracic organs | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1.5 | C37-C38 |
| Bone | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1.5 | C40-C41 |
| Mesothelioma | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.7 | C45 |
| Breast | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1.5 | C50 |
| Prostate | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 2 | 2 | 6 | 11.9 | C61 |
| Testis | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.7 | C62 |
| Kidney, ureters etc. | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.7 | C64-C66;C68 |
| Bladder | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 5 | 6.0 | C67 |
| Brain, nervous system | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 1 | 5.2 | C70-C72 |
| Hodgkin's disease | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.7 | C81 |
| Non-Hodgkin's lymphoma | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1.5 | C82-C85;C96 |
| Multiple Myeloma | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.7 | C90 |
| Myeloid leukemia | 7 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3.7 | C92-C94 |
| Other & unspecified | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 3 | 4 | 9.7 | Other |
| TOTAL | 118 | 0 | 1 | 2 | 0 | 1 | 1 | 2 | 4 | 4 | 4 | 5 | 10 | 12 | 17 | 15 | 12 | 44 | 100.0 |

Table 35 Frequency of Cancer Deaths among Bahraini Females, 2014

| CANCER SITE | ALL AGE AGES | 0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75+ | % OF TOTAL | ICD (10TH) |
|-------------------------|--------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|-----------|-----------|-----------|-----------|-----------|-----------|------------|-------------|
| Other oropharynx | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0.8 | C10 |
| Nasopharynx | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.8 | C11 |
| Stomach | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.8 | C16 |
| Small intestine | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0.8 | C17 |
| Colorectum | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | 8.4 | C18-C21 |
| Liver | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2.3 | C22 |
| Gallbladder etc. | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 3.1 | C23-C24 |
| Pancreas | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 2 | 3.8 | C25 |
| Trachea, bronchus, lung | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 3.1 | C33-C34 |
| Connective, soft tissue | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.8 | C47;C49 |
| Breast | 42 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 6 | 4 | 9 | 5 | 3 | 3 | 9 | 32.1 | C50 |
| Cervix Uteri | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 3.8 | C53 |
| Corpus Uteri | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2.3 | C54 |
| Uterus unspecified | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 3.1 | C55 |
| Ovary | 10 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 7.6 | C56 |
| Placenta | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.8 | C58 |
| Kidney, ureters etc. | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1.5 | C64-C66;C68 |
| Bladder | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 3.1 | C67 |
| Brain, nervous system | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 3.1 | C70-C72 |
| Thyroid | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1.5 | C73 |
| Adrenal gland | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.5 | C74 |
| Non-Hodgkin's lymphoma | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2.3 | C82-C85;C96 |
| Myeloid leukemia | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2.3 | C92-C94 |
| Leukemia unspecified | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.8 | C95 |
| Other & unspecified | 13 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 9.9 | Other |
| TOTAL | 131 | 0 | 4 | 0 | 1 | 0 | 1 | 2 | 4 | 4 | 8 | 14 | 11 | 19 | 15 | 11 | 13 | 24 | 100 |

REFERENCES

1. GLOBOCAN 2012, International Agency for Research on Cancer. Available at: <http://globocan.iarc.fr>
2. Gulf Centre for Cancer Control and Prevention. (2013) Cancer incidence among nationals of the GCC states, 1998–2009, Riyadh, Saudi Arabia.
3. Parkin DM et al., eds. Cancer incidence in five continents. Volume VIII. Lyon, International Agency for Research on Cancer, 2002 (Scientific Publication No.155).
4. Alsayyad J and Hamadeh R. Cancer incidence among the Bahraini population: a five-year (1998-2002) experience. *Ann Saudi Med* 2007. 27(4): 251-258.
5. Hamadeh RR, Alsayyad J. Cancer Incidence among Nationals in Bahrain. In: Asian Pacific Organization for Cancer Prevention Cancer Report 2010. Tuncer AM (Ed). New Hope in Health Foundation, Ankara, Turkey 2010, Pp 295-296. ISBN: 978-975-567-058-4.
6. General Directorate of Statistics, Central Informatics Organization. (2014).
7. Census Summary Result 2010 – Population, Housing, Buildings, Establishments and Agriculture Census. Retrieved from:
http://www.cio.gov.bh/CIO_ARA/English/Publications/Census/2011%2009%2018%20Final%20English%20Census%202010%20Summary%20%20Results%20-%20Review%201.pdf
8. Segi, M. (1960) Cancer Mortality for Selected Sites in 24 Countries (1950–57). Department of Public Health, Tohoku University of Medicine, Sendai, Japan.
9. Doll, R., Payne, P., Waterhouse, JAH. Eds (1966). Cancer Incidence in Five Continents, Vol I. Union Internationale Contre le Cancer, Geneva.

